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Changes in c-Myb Activity during Proliferation
By
Anita M. Quintana
B.S. Microbiology
Ph.D Biomedical Sciences
Abstract

c-myb encodes a transcription factor and is the cellular parent of the vmyb oncogene, which causes acute myeloid leukemia in chickens and mice.
Truncation or deletion can unmask the oncogenic potential of the human c-myb
gene and recent reports have established that the human c-myb locus is subject
to translocation and duplication in human pediatric T-ALL. c-Myb is expressed in
all proliferating hematopoietic progenitor cells and has been implicated in some
solid tumors, such as breast and colon. Evidence suggests that c-Myb activity is
cell type specific and cell cycle dependent. For example, c-Myb interacts with
cyclin D1 and CDK6 in Jurkat T-cells and this interaction inhibits c-Myb activity.
Furthermore, there are numerous versions of Myb within a cell, each of which
has a conserved DNA binding domain, but regulates different sets of
endogenous genes. So it seems activity and specificity are regulated by domains
outside of the DNA binding domain and possibly in a cell cycle-dependent
manner. We hypothesized that protein interactions and post-translational
modifications affect c-Myb activity in a proliferation dependent manner. We
combined two model cell lines, MCF-7 cells and Jurkat T-cells, to characterize cMyb specificity in different populations of proliferating cells. We found that c-Myb
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protein dynamically repositions from one gene to the next in different phases of
the cell cycle. Furthermore, mitotic signals such as estrogen stimulation, affect
the detection of conserved domains in the c-Myb proteins suggesting that protein
interactions change while c-Myb is bound to target genes. We conclude that cMyb activity and specificity are regulated by dynamic oscillations in binding and
in the event that c-Myb itself does not reposition its binding, partners come and
go to its affect activity.
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Chapter I: Introduction
Summary
c-Myb has been implicated in the control of proliferation and differentiation
in a number of different cell types. Although several mechanisms for regulating
the expression levels and the activity of c-Myb have been identified, several
types of evidence suggest that c-Myb has different activities in different cell
types, and even at stages of the cell cycle. For example, c-Myb binds to and
regulates multiple different cell cycle regulated promoters such as CDC2,
CCNB1, and CCNA1, each of which is essential for a different stage of the cell
cycle. Furthermore, c-Myb and its truncated-mutated oncogenic derivative
regulate distinct endogenous sets of genes. Thus, protein domains outside the
DNA binding domain that are targets for post-translational modifications and
protein-protein interactions control c-Myb specificity. This suggests that c-Myb
activity is highly regulated and modified by a variety of different signaling
pathways and interactions, even in a time dependent manner. In this chapter the
mechanisms that regulate c-Myb activity during the cell cycle will be highlighted
and how changes in these mechanisms could lead to transformation and
leukemogenesis will be addressed.
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I. The importance of c-Myb in differentiation, proliferation and oncogenesis
The c-Myb protein is a transcription factor with a highly conserved DNA
binding domain near its N-terminus (Figure 1) and several additional conserved
motifs comprising a large C-terminal domain involved in negative regulation,
control of its degradation and half-life, transcriptional activation, and the selection
of specific target genes [1, 2]. The interest in c-Myb stems less from its role as a
transcriptional regulator, since it activates genes in a manner similar to many
other transcription factors, and more from the dualities of its functions. For
example, different versions of c-Myb can be either a critical regulator of normal
cells or a potent oncoprotein, and the protein is required for the opposing
processes of cell proliferation as well as for terminal differentiation. Although the
c-myb gene was amongst the first cellular proto-oncogenes to be identified and
studied, the activities of the c-Myb protein seem paradoxical and its functions
remain enigmatic. Because of the changes in activity and specificity,
nomenclature becomes important. For the purposes of this chapter we will
distinguish between c-Myb the protein and c-myb the gene (MYB) in order to
differentiate between these cellular forms and the viral forms, v-Myb and v-myb.
The origin of c-myb and v-myb

The c-myb gene is the cellular progenitor of the viral oncogene, v-myb,
which transforms immature hematopoietic cells in culture and induces leukemia
in animal models [3-5]. The viral derivative of c-myb originated in two chicken
retroviruses, Avian Myeloblastosis Virus (AMV) and the E26 virus, each of which
encodes a truncated and mutated version of the c-Myb protein [6, 7]. Both
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viruses are potent inducers of acute leukemia in chickens and rapidly transform
immature cells by blocking their differentiation and promoting growth factordependent proliferation in vitro [8-10]. When the viral oncogenes are expressed
from murine retroviruses, they are also capable of inducing leukemia in mice [11,
12], and the c-myb gene is frequently activated by retrovirus insertions in mouse
models of leukemia [13-17]. Even though the v-Myb proteins are potent
oncoproteins, the cellular parent, c-Myb does not induce tumors or leukemia in
animals, even when constitutively over-expressed [18]; c-Myb can only transform
cells in tissue culture in specialized situations [19]. The viral oncoproteins harbor
deletions and point mutations and these modifications to the structure of c-Myb
greatly enhance transforming activity [20]. The mutations are now known to affect
specificity and target gene selection, since c-Myb and AMV v-Myb regulate
distinct sets of endogenous genes [21]. This is one of the dualities of c-Myb: that
relatively minor changes in its structure can completely change the spectrum of
genes that it regulates. The unexpected plasticity in c-Myb activity may be its
signature trait, and could explain its relatively underappreciated role as an
oncoprotein in human malignancies.
Expression of c-Myb in human tumors

Because the v-myb oncogenes induce leukemia in animals, most of the
attention on c-myb as a human oncogene has focused on its role in leukemia and
other hematopoietic malignancies. In general, the expression of c-myb RNA and
c-Myb protein in normal hematopoietic cells correlates with proliferation and the
level of expression decreases as cells terminally differentiate [22]. Thus, the
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highest levels of c-Myb are found in immature, proliferating cells, and little or no
c-Myb is found in mature, differentiated, non-dividing cells [23]. In malignancies,
the expression of c-Myb is relatively high in most if not all human leukemia such
as T-ALL, B-ALL, AML and CML, often at much higher levels than in normal cells
[24-27]. Elevated levels are also detected in several types of solid tumors, most
notably colon and breast [28-31]. However, the association between c-myb
expression and proliferation has led to the question of whether c-myb is a causal
factor in human tumorigenesis, or merely a marker of higher proliferation in
tumors compared to normal cells. Recently, a number of studies suggest a
causal role by identifying c-myb gene amplifications and/or recurrent
rearrangements in a variety of human tumors including leukemia and
lymphomas, medulloblastomas, squamous cell carcinomas, small cell lung
carcinomas and head and neck tumors [27, 32-37]. This evidence strongly
suggests that amplification and/or mutation of the c-myb gene plays an important
and causal role in the development of a wide variety of human hematopoietic,
epithelial and neural tumors. Therefore, understanding the functions and
activities of the c-myb gene and c-Myb protein are critical for understanding a
variety of normal processes and for devising treatment strategies targeting this
important human oncogene.
Regulation of hematopoietic cell proliferation and differentiation

The primary role of the c-Myb protein in normal development was
established by constructing and analyzing c-myb-/- knockout mice, which have
normal yolk sac hematopoiesis but succumb due to a defect in definitive
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erythropoiesis in the fetal liver [38]. Reduction in the level of c-Myb by conditional
CreLox alleles rather than complete eradication has demonstrated that lower
levels of c-Myb can promote a healthy generation of progenitor cell populations,
but decrease their ability to commit to different lineages [39]. For example,
reduced levels (5-10% of wildtype mice) of c-Myb lead to increases in
monocytes, macrophages, and megakaryocytes. While reduced levels can favor
the formation of specific myeloid cells, other lineages such as erythroid cells are
decreased. Reduced levels of c-Myb increase immature erythroid progenitor
populations, but decrease the level of mature erythroid cells relative to wildtype
littermates. These results have demonstrated that thresholds of c-Myb
expression and activity are important for cell fate decisions and can impact key
differentiation steps. These data suggest that low levels of expression can lead to
functional proliferating populations, but higher degrees of expression may be
needed for accurate differentiation.
The c-Myb protein is expressed in all proliferating progenitor cell
populations and during differentiation the degree of c-Myb expression declines
[40-42]. Constitutive c-Myb expression blocks differentiation [43], and anti-sense
oligonucleotides inhibit proliferation both in vitro and in vivo [44-48]
demonstrating that c-Myb is an important regulator of proliferation, at the
expense of differentiation. However, the identification of many target genes [1]
that are expressed in terminally-differentiated cells suggests that c-Myb also
plays a role in stimulating differentiation, which seems contradictory.
Understanding this paradox: that c-Myb regulates both differentiation and
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proliferation, may be the key to understanding the importance and uniqueness of
c-Myb as an oncoprotein.
The published results from various laboratories establish that c-Myb has
clear biological phenotypes, but do not explain how one protein can have
different and apparently contradictory functions. One explanation could be that cMyb has different functions in different cell types. Most of the studies linking cMyb to the regulation of proliferation have been performed with hematopoietic
cells, usually with leukemia-derived cell lines. For example, c-Myb binds to the
CCNA1 (Cyclin A1) and CCNB1 (Cyclin B1) promoters and activates their
expression in myeloid leukemia-derived cell lines [49, 50]. In these cells, where
c-Myb is highly expressed, it could play an important role in promoting
progression through the cell cycle, which could in turn be regulated by by c-Myb
interactions with Cyclin D1 [51] and Cyclin Dependent Kinases 4 and 6 [52]. The
interactions with Cyclin D1 are different for c-Myb and v-Myb, raising the
intriguing possibility that regulation of the cell cycle is an integral part of the
oncogenic potential of c-Myb [51]. It is not yet clear whether c-Myb also regulates
the expression of the Cyclin genes in normal cells, or in only a subset of normal
cells such as hematopoietic cell progenitors, although there is some evidence
that c-Myb may regulate the Cyclin E1 gene in some proliferating epithelial cells
[53] and that c-Myb plays an important role in the estrogen-induced proliferation
of mammary cells [54], suggesting that the link between c-Myb and proliferation
may be more general.
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There is also ample evidence that c-Myb plays an important role in
hematopoietic cell differentiation. The original c-Myb target gene, mim-1, is only
expressed in differentiating neutrophils [55], and this specificity is linked to the
requirement for combinatorial cooperation with NF-M, the chicken equivalent of
C/EBPbeta [56]. This is a model for the lineage specificity of other c-Myb target
genes, which likely require that c-Myb cooperates with other regulators. Such
targets include lineage specific genes like neutrophil elastase [57, 58] and
myeloperoxidase [59], as well as target genes that are expressed only in
immature cells such as CD34 [60] and c-KIT [61, 62].
Alternatively, c-Myb activity could be qualitatively different in different cell
types because of lineage-specific post-translational modifications, such as serine
or threonine phosphorylation, arginine methylation, lysine acetylation or others
[2]. The post-translational modifications could affect the specificity and selection
of target genes by c-Myb, analogous to the way point mutations in v-Myb change
its activity. These possibilities and the effects of post-translational modifications
on c-Myb activity will be discussed below.
Different levels of c-Myb may lead to different outcomes

In addition to qualitative changes in c-Myb activity, or differences in which
cooperating factors are available in different lineages, there is also evidence that
quantitative changes in c-Myb levels lead to the activation of different pathways.
As discussed previously, in mouse models low levels of expression favor the
formation of macrophages and monocytes, whereas higher levels favor
erythropoiesis [39]. In general, the level of c-Myb activity in different cell types is
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difficult to assess, especially since c-myb RNA levels decrease during
differentiation [41-43, 63]. How is it possible that ablation of c-myb is lethal, but
small changes in expression dictate lineage selection? While it is true that c-Myb
is essential, a threshold of expression may exist that modulates proper
hematopoietic cell differentiation. For example, despite the fact that c-myb RNA
levels decrease substantially during lymphoid cell differentiation, c-Myb protein
binds to and activates the promoters of genes that are expressed in fully
differentiated cells such as the VDJ recombinase RAG2 [64, 65]. RAG2 is only
expressed in fully differentiated T and B-cells, which express little if any c-myb
mRNA, yet c-Myb protein can cause activation of this gene during an immune
response. Results such as these suggest that the level of c-myb RNA makes a
poor predictor of c-Myb protein activity. Therefore, it seems likely a major part of
c-Myb protein regulation occurs through post-translational changes such as
stability, modifications, protein interactions that can be reversed quickly,
depending on cell context, and using residual c-Myb protein, even in cells that
express little or no c-myb mRNA.
II. Context-specific changes in c-Myb activity
Structural and conserved domains

The dominant conserved feature in the c-Myb protein is the DNA binding
domain near the N-terminus, which is identical in c-Myb proteins from species as
diverse as humans, mice and chickens (Figure 1). The c-Myb DNA binding
domain has been used as a signature to identify two additional transcription
factors, A-Myb (MYBL1) and B-Myb (MYBL2), which have nearly identical DNA
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binding domains and similar overall structures, but very different functions. Both
crystal and solution structures of the DNA binding domain, either free in solution
or bound to DNA, have been determined (reviewed in [1]). Interestingly, even the
parts of the DNA binding domain that do not contact DNA have been perfectly
conserved amongst vertebrate c-Myb proteins, suggesting that the DNA binding
domain also serves as an important protein binding or docking surface [1].
Indeed, several proteins have been identified that interact with the c-Myb or vMyb DNA binding domains [51, 66-68]. More importantly, three of the mutations
in the AMV v-Myb protein change amino acids mapping to protein-interaction
surfaces in the DNA binding domain [1]. These amino acid changes alter the
activity of the protein [56], change the phenotypes of transformed cells [69] and
shift the activity on some target genes [70], showing that relatively subtle
changes in the structure of c-Myb, even affecting just a single amino acid
residue, can change which target genes are regulated.
There are numerous regions within the c-Myb protein that are highly
conserved and have been shown to have very important functions. The
conserved trans-activation domain, amino acids 275-327, is essential for the
transcriptional activity of c-Myb and v-Myb as measured in reporter gene assays
[71, 72]. The extreme C-terminal domains negatively regulate the protein and
truncation or deletion of this region causes increased c-Myb activity in some
assays [66, 73]. The EVES motif, near the C-terminus and centered at amino
acid 530, is involved in negative regulation by inducing an intramolecular foldback mechanism and interacting with the DNA binding domain [66]. As discussed
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further below, the c-Myb protein has many activities that contribute to its ability to
regulate genes and control proliferation and differentiation.
Myb proteins have chromatin remodeling activities

Although the Myb DNA binding domain defines a family of related
proteins, it recently acquired the additional classifier as a SANT domain protein,
defined by a conserved motif found in multiple chromatin remodeling enzymes
with homology to the Myb DNA binding domain [74]. The SANT domain is named
for ‘switching-defective protein 3 (Swi3), adaptor 2 (Ada2), nuclear receptor corepressor (N-CoR) and transcription factor (TF)IIIB’[75]. The structural link
between c-Myb and these well-known chromatin-remodeling enzymes suggests
that c-Myb could also play a role in chromatin remodeling. Although c-Myb does
not have enzymatic chromatin remodeling activity, it can modulate chromatin
remodeling through interactions with histone tails or through interactions with
proteins that modify histone residues. The DNA binding domain of c-Myb has
been shown to bind and facilitate the acetylation of the N-terminal tails of
histones H3 and H3.3, and this interaction is disrupted by the v-Myb mutations in
the DNA binding domain [76], suggesting that changes in the chromatin
remodeling activities of c-Myb are important for unleashing its oncogenic activity.
Fine mapping of the conserved residues within the c-Myb DNA binding domain
also led to the identification of an acidic patch required for interactions with the Nterminal tails of histone H4 [77], suggesting that the c-Myb DNA binding/SANT
domain may have multiple histone binding activities that are part of its chromatin
remodeling function.

10

In addition to direct interactions with histone tails, c-Myb can also direct
chromatin remodeling by interacting with enzymes that modify histones. For
example, c-Myb is found in a complex with the Mixed-Lineage Leukemia protein
(MLL), a SET domain-containing histone methyltransferase that is frequently a
component of fusion proteins produced by chromosome translocations in human
acute leukemia. MLL methylates lysine 4 of histone H3 (H3K4), which is an
important step in gene activation. A third protein, Menin, an MLL interacting
partner [78], mediates the interaction between MLL and c-Myb. Thus, the gene
activation activity of MLL may be directed to specific target genes through MLLMenin-Myb complex formation. Since MLL is a known human oncogene, this
association suggests a possible mechanism of c-Myb in leukemogenesis.
The Myb DNA binding domain recognizes sites in DNA matching a loose
consensus sequence: (C/T)AAC(G/T)G [79]. Because this sequence is
degenerate, it is expected to occur on average about once per kilobase, or more
than 3 million times in the haploid human genome. Clearly, other domains in the
c-Myb protein, which likely facilitate specific protein-protein interactions, must
also play an important role in determining which binding sites are preferred and
therefore which genes are regulated. This is illustrated best by microarray
experiments that identified hundreds of target genes that were activated or
repressed when different Myb proteins were ectopically expressed either in
breast cancer cell lines or in primary human monocytes. To a first approximation,
despite having nearly identical DNA binding domains, c-Myb activated totally
different sets of genes than either A-Myb or B-Myb [80] and completely different
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genes than were activated by its oncogenic derivative, v-Myb [21]. Furthermore,
domain swap experiments showed that the biggest effects on target gene
selection were caused by the differences outside the DNA binding domains,
which were essentially interchangeable [70]. Thus, the regions of c-Myb outside
the DNA binding domain, especially the large C-terminal domains that are often
referred to as the transcriptional activation and/or negative regulatory domains,
are in fact deeply involved in the selection of target genes and in determining the
specificities of the c-Myb protein in different situations.
Myb-like domains in other proteins

In addition to chromatin remodeling proteins, Myb-like DNA binding
domains are found in the important regulator DMP1, a Cyclin D1-binding
transcriptional regulator that has tumor suppressor activity [81, 82], as well as in
a group of important regulators called the Telebox proteins [83]. The Telebox
domain is found in the human TRF1 and TRF2 proteins and is responsible for the
ability of these proteins to bind telomere repeats in DNA after forming
homodimers [84]. This mechanism sets the Telebox proteins apart from Myb
proteins, since the latter do not form homodimers. Although the Myb-like domains
are important for telomere binding, the Telebox proteins can bind to nontelomeric DNA as well, suggesting that these domains are specialized and may
also have other functions within the cell [85]. Interestingly, TRF1 and c-Myb also
share the ability to interact with the Pin1 proline isomerase, which regulates
protein conformation in a phosphorylation-dependent manner [86, 87]. The c-Myb
protein also interacts with the proline isomerase Cyp40, which induces
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conformational changes in c-Myb but not v-Myb [67], suggesting that interactions
with enzymes like Cyp40 and Pin1 could play an important role in suppressing
the oncogenic activity of c-Myb.
Post-translational modifications of c-Myb

The c-Myb protein is subject to numerous post-translational modifications
that can affect its activity (Figure2A). SUMOylation is the reversible process of
covalent modification of proteins with small ubiquitin like modifiers (SUMO).
There are four SUMO proteins and c-Myb is SUMOylated at several different
residues in response to different cellular signals. SUMO modification of c-Myb
has been divided into distinct groups. The first group is SUMOylation by SUMO
protein 1 [88, 89] and occurs in the negative regulatory domain through an
interaction with the SUMO modifying enzyme UBC9 [88]. This modification is
highly dependent upon the presence of lysine 523 and results in decreased cMyb transactivation activity. Although SUMOylation of c-Myb by SUMO 2/3
occurs at the same sites, it is a response to stress and requires a separate E3
ubiquitin ligase [90]. SUMO 2/3 modification causes a reduction in the activation
of c-Myb target genes [90]. SUMO modification is dependent on the ability of cMyb to interact with either UBC9 or PIASy and the type and extent of SUMO
modification changes based upon these protein interactions. These results
suggest that changes in protein interactions and post-translational modifications,
even those that occur outside of the DNA binding domain, can have a dramatic
effect on c-Myb activity.
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Turnover of the c-Myb protein is mediated by ubiquitin and the 26S
proteosome. In malignancies c-Myb has a more pronounced half-life compared
with normal cells and mutation and deletion of specific regions/residues leads to
increased stability [91]. As described, the c-myb locus is subject to retroviral
insertions that lead to leukemia in mouse models. In many cases these insertions
cause truncation of the protein at the N and C-termini and results have confirmed
that these truncations, especially in the C-terminus cause increased stability [92].
Therefore, truncation is a simple mechanism by which activity can be regulated.
For example, truncated versions may bind to the same target genes as full-length
c-Myb except truncated versions are more readily available therefore enhancing
c-Myb activity at a specific set of target genes. Since truncation leads to changes
in the C-terminal domain, a domain that is highly modified, it is likely that during
different stages of proliferation, S-phase versus M-phase, c-Myb is differentially
ubiquitinated and has different stability. The stability of c-Myb would allow the
protein to interact with specific proteins in a time dependent manner and activate
different cyclin genes in different phases of the cell cycle. Results demonstrating
c-Myb is constitutively ubiquitinated and does not have altered stability in
synchronized cells at different stages of the cell cycle [93] suggests that the
stability of full length c-Myb is not a primary means of regulating activity in a cell
cycle dependent manner. These data suggest that c-Myb protein does not exhibit
increased turnover during the cell cycle and a substantial amount is available at
each stage of the cell cycle in cancer cells. Other mechanisms must be readily
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available to govern c-Myb activity because a substantial amount of c-Myb is
expressed during independent stages of the cell cycle.
Ubiquitin is most commonly associated with degradation, but it is possible
that combinations of modifications such as ubiquitin and phosphorylation are
needed to properly degrade c-Myb. Coincidentally, results have demonstrated
that phosphorylation of the C-terminus induces conformational changes that
facilitate proper degradation [94]. Interestingly, hyper-phosphorylated c-Myb and
hypo-phosphorylated c-Myb have the same affinity for DNA suggesting that
under some conditions the turnover of c-Myb can regulate DNA binding.
However, the ability to bind DNA with the same affinity does not translate into
activity. These data reinforce the concept that modifications are connected to one
another and function as a unit to determine c-Myb activity and binding capacity.
One of the problems with many of these experiments is that they have
only used relatively crude measures of c-Myb activity to judge the effects of the
modifications. Since the cloning of the original Myb-regulated target gene, mim-1,
it has been clear that the ability of c-Myb and v-Myb to activate endogenous,
chromatin-embedded target genes does not correlate with the ability to activate
plasmid-based reporter gene assays [55, 56, 69]. With the advent of microarray
assays, the complexities of target gene selection by different versions of c-Myb
have become evident [21, 80], and it seems likely that SUMOylation and other
post-translational modifications may be responsible for shifting or determining the
selection of target genes by c-Myb. It will be necessary to test different versions
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of c-Myb in more sensitive, unbiased gene activation assays to determine how
these modifications affect c-Myb in the context of the cell.
Myb interacts with proteins during induced acetylation

c-Myb interacts with numerous co-activators and in some cases, these
interactions affect Myb activity. Mutation of c-Myb can affect these interactions.
One such mutation is M303V, which disrupts an interaction with the
transcriptional coactivator and histone acetyltransferase, p300. In a mouse model
system, this disruption leads to defects in hematopoiesis and promotes cellular
proliferation [95] suggesting that the interaction between c-Myb and p300 affects
cell fate decisions. p300 acetylates c-Myb at three lysines within the C-terminal
domain and mutation of these residues to alanine leads to an increased DNA
binding ability and increased transactivation activity [96]. c-Myb can also interact
with the p300-related CREB Binding Protein (CBP) near the c-Myb
transactivation domain, resulting in increased transactivation activity [97, 98].
CBP and p300 can acetylate the same residues in c-Myb, suggesting that these
two proteins can have redundant functions, but it is unclear which interacting
partner is preferred during different developmental stages or in different growth
conditions. For example, CBP can interact with the transactivation domain or the
negative regulatory domain [98], this difference could account for preferences in
which residue gets modified, which in turn might reflect differences in the
chronological sequence of protein modifications that dictate c-Myb specificity. If
there is a context specific code [2] mediating c-Myb activity then the sequence of
modifications could lead to changes in c-Myb specificity.
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Varied effects of phosphorylation on Myb activity

Phosphorylation of c-Myb has been reported to have several different
effects, including increased or decreased DNA binding activity, decreased
stability, defects in negative regulation, and phosphorylation-dependent protein
interactions with a number of cofactors [87, 94, 99-105]. Direct phosphorylation
has been demonstrated by kinases including Pim1, Casein Kinase II, and p42
Mitogen-Activated Protein Kinase [68, 106, 107]. Phosphorylation can impact
specific protein interactions, which could change the activity and/or specificity of
c-Myb and determine which target genes become activated. For example,
phosphorylation affects protein interactions with HIPK1 and Fbw7 [105, 108],
both of which have unique effects on c-Myb activity. Characterization of the
interaction between HIPK1 and c-Myb at the mim-1 promoter established that
this interaction inhibits activation of mim-1. On the other hand, when c-Myb
interacts with Fbw7, c-Myb is subject to ubiquitination and degradation. Thus,
modifications can change c-Myb activity directly or in conjunction with other
proteins. These studies were performed using plasmid-based reporter gene
assays, or a single target gene such as mim-1, so the effects of phosphorylation
on target gene selection is not known. Therefore, global differences in Myb
activities may be dictated by phosphorylation status [80].
Regulation is time dependent: A Mechanism of c-Myb regulation

c-Myb interacts with a wide array of proteins (Figure 2B). Some protein
interactions may be dependent on or lead to new post-translational modifications.
In addition, post-translational modifications may occur in a chronological order,
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analogous to the way modifications are added sequentially to histones during
transcriptional activation. These changes in post-translational modifications could
account for the ability of c-Myb to bind to and regulate different genes in different
biological processes. As discussed, c-Myb regulates the CCNA1, CCNB1, and
CCNE1 genes [50, 53, 109] during the cell cycle. In the time-dependent cell
cycle, c-Myb could be bound to these genes all the time but only participate in
regulating the genes in specific stages of the cell cycle. Alternatively, c-Myb
binding to specific promoters could change in a time-dependent manner,
oscillating between different promoters as the cells progress through the cell
cycle. To distinguish between these possibilities, it will be necessary to measure
the association of c-Myb with different target genes as cells progress through the
cell cycle.
The idea that c-Myb activity and target gene selection could change in a
time-dependent manner during the cell cycle runs counter to expectations of
transcription factor activities based solely on plasmid-based reporter gene
assays. This may be the reason that the ability of c-Myb to activate endogenous
genes does not correlate with the ability to activate reporter genes. If posttranslational modifications affect target gene selection by c-Myb, it is likely that
the cell contains multiple pools of c-Myb with different, perhaps overlapping
specificities. For example, phosphorylation of c-Myb is likely to be substoichiometric, defining a subset or pool of protein with a unique posttranslational modification and perhaps a unique specificity for select target
genes. However, modification of c-Myb is not limited to phosphorylation since the

18

protein can also be acetylated [96, 98], SUMOylated [88-90], and ubiquitinated
[93], and is likely also to be modified in other ways. Potentially, each modification
could distinguish a specific sub-population of c-Myb proteins with a unique
spectrum of activities, directed toward a specialized subset of target genes by
unique protein-protein interactions that are controlled by the modifications.
Regulating transcription by post-translational modifications or protein
interactions offers the ability of regulating activity in a dynamic, time-dependent
manner since these types of modifications can occur rapidly in response to
mitogenic signals. There is very little known about how c-Myb activity might be
affected by upstream signaling pathways, such as cytokine receptor pathways or
oncogenic tyrosine kinases. Now that assays are available to follow subtle
changes in c-Myb target gene selection, it will be interesting to see how such
signaling pathways might affect c-Myb activity and its choice of target genes in
specific situations in normal cells and in malignancies.

Mechanisms regulating c-Myb in T-cell and B-cell Development

Although the original c-myb knock out animals demonstrated the
requirement for c-Myb expression in erythropoiesis, more recent experiments
using conditional knock out strains have shown that c-Myb is also necessary for
the development of the lymphoid lineages. Conditional knockdown of c-Myb in
mice suggests that c-Myb is critical for three points of thymocyte development:
double negative, double positive, and single positive [110]. Knockdown of c-Myb
has different effects on each stage of development. For example, increases in
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double negative thymocytes (DN) upon c-Myb knockdown is not due to defects in
the cell cycle or cell survival. In contrast defects in the double positive (DP) Tcells to single positive (SP) cells is related to defects in cell survival [110]. DN
cells go through stages of DN (1-4) development and it was demonstrated that at
the DN3 stage, levels of TCRß, a c-Myb target gene were decreased, resulting in
defects in differentiation [110]. These data suggest that as specific cell types (i.e.
different T-cell stages) progress through differentiation the same protein, c-Myb,
can facilitate multiple processes (Figure 3). It is likely that c-Myb, or more
specifically a unique subset of c-Myb, binds to and regulates the TCR during
DN3 development, but a different subset of c-Myb, DP specific c-Myb, regulates
other genes to affect cell survival. In theory, this mechanism would affect
proliferation by regulating target genes such as cdc2 [111] in a cell cycle
dependent manner. c-Myb is essential for proper proliferation and regulates
genes such as cdc2, but c-Myb can also regulate genes such as Bcl-2, an antiapoptotic gene [112, 113]. These results suggest that different sub-populations of
c-Myb can regulate different genes in different cell types, or more specifically the
same types of cells undergoing different fates. The c-Myb proteins in these subpopulations of cells are likely defined by different post-translational modifications
and protein interactions that affect the target gene selection by c-Myb. Thus,
knockdown of c-Myb in T-cells has identified different c-Myb subpopulations,
each of which is essential for a key stage in cellular development and
progression. Recently other groups have expanded on the idea that c-Myb
affects different subsets of thymocytes and have demonstrated that during
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progression from DP to SP c-Myb regulates Bcl-xL, an anti-apoptotic gene and
during c-Myb knockdown, DP thymocytes undergo apoptosis leading to a
decrease in specific subsets of SP cells [114]. This concept of sub-populations of
c-Myb regulating discrete stages of differentiation can be expanded to other cell
types, in particular B-cells, where c-Myb regulates the survival of a specific
subset of B-cells [115].
c-Myb’s role in T-cell and B-cell development is complex and it is clear
that c-Myb target genes vary in different subpopulations of cells. More
specifically, the activity of c-Myb varies in different stages of differentiation. This
raises an interesting question: If only a subset of c-Myb molecules is involved in
regulating specific genes, what is the rest of the c-Myb doing? Is the cell cycle
specific fraction of c-Myb expressed, but not active during the cellular response
to differentiation cues? Where does it go if its not bound to genes? Some c-Myb
interacting partners have variable localization and could sequester c-Myb protein.
For example, the interaction between c-Myb and FLASH leads to colocalization
into nuclear speckles, however only a fraction of c-Myb is found in these
speckles [116]. Unfortunately, it is not clear how many subpopulations of c-Myb
exist within a given cell type, or where those subpopulations are localized.
III. Mechanisms that control c-Myb activity and specificity
Alternative RNA splicing produces multiple forms of c-Myb

In addition to post-translational modifications, subpopulations of c-Myb
can also be produced through alternative RNA splicing. The c-myb gene contains
15 exons and undergoes alternative splicing in both cancer cells and normal cells
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[117-120]. The vast majority of alternative splicing occurs in exons 6-15 and
excludes the exons that encode the DNA binding domain. Thus, almost all of the
variant c-Myb proteins encoded by alternatively spliced mRNAs contain the
normal DNA binding domain, but have changes in the large C-terminal domains
controlling transcriptional activation, negative regulation and target gene
specificity [118]. For example, the addition of alternative exons such as exon 6A,
which results in a 400 bp insertion between exon 6 and 7, have been described
in normal cells and cancer cells [119]. Exon 9 can form up to four different
variants in both chickens and humans and at least two of them are found in
hematopoietic cells [118, 121, 122]. With the identification of additional c-Myb
target genes and the availability of assays that can detect differences in target
gene selection by different versions of c-Myb, it has become clear that many of
the proteins encoded by splice variants have distinct transcriptional activities and
activate different sets of genes than the “wild type” c-Myb [118]. These results
greatly increase the amount of complexity that is possible in the targeting of
genes by c-Myb, since different subpopulations of the protein, encoded by
different versions of the mRNA, could regulate entirely different sets of target
genes.
Comparisons of different types of cells have shown that different patterns
of c-myb mRNA splicing are found in different cell lineages [118], suggesting that
alternative mRNA splicing is as carefully regulated as any other aspect of
differentiation. In addition, much higher levels of c-myb alternative splicing are
found in leukemia than in normal bone marrow cells [118], suggesting that the
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mechanisms controlling alternative splicing are defective or modified in
malignancies. Thus, amplified alternative splicing may be a novel mechanism for
activating oncogenes like c-myb, which are capable of producing variant proteins
with different, perhaps transforming, activities. This idea is strengthened by
recent findings showing that regulators of alternative RNA splicing are
themselves oncogenes [123, 124], presumably because they cause the
production of alternatively-spliced mRNAs that encode proteins with
altered/oncogenic activities, similar to the altered activities displayed by v-Myb
compared to c-Myb.
One of the major questions that remains is, do different versions of c-Myb,
encoded by different splice variants or produced by sub-stoichiometric posttranslational modifications, compete for the same target gene promoters. For
example, phosphorylation of specific residues in the N-terminus of c-Myb may
only occur on a fraction (1%) of the total molecules of c-Myb. These
phosphorylated molecules may have different activities and different binding
specificities, due to different cooperative interactions with other proteins that bind
some target promoters. If subpopulations of c-Myb are able to bind specific
subsets of target promoters, without really competing with the vast bulk of the
protein that has a different specificity, then even relatively rare forms of the
protein could make important contributions to the patterns of genes that get
expressed, and could contribute to transformation. Additional experiments will be
required to determine whether different versions of c-Myb, which appear to have
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distinct target gene specificities, are able to regulate their target genes in the
presence of other, more abundant versions of the protein.
Regulation of c-myb by microRNAs

MicroRNAs are small non-coding RNAs approximately 22 nucleotides in
length and were first discovered in plants as regulatory RNAs that can regulate
the stability of RNA transcripts [125, 126]. These non-coding RNAs are derived
from primordial RNAs that are cleaved into one or more microRNAs
complementary to regions within the 3’ untranslated region of specific target
mRNAs. Genes that encode microRNAs such as lin-4 and let-7 were discovered
first in C. elegans and play important roles in the regulation of larval development
[126]. In mammals, deregulated expression of microRNAs can influence a large
number of genes and can contribute to many different types of cancer including
breast and oral cancer [127-130].
The c-myb 3’ untranslated region (UTR) is extensive and contains many
potential binding sites for microRNAs. MiR150 is expressed in resting T and Bcells, but not proliferating progenitors [131] and deletion of miR150 can cause an
increase in c-myb expression and expansion of the B1 subset of B-cells. These
observations were more pronounced in B-cells than T-cells presumably because
the level of miR150 in T-cells is reduced relative to B-cells [132]. The regulatory
relationship between miR150 and c-myb is conserved in zebrafish suggesting
that this ancient regulatory mechanism has been conserved throughout
vertebrate evolution [133]. The miR150 mechanism also regulates c-myb
expression in other cell types. For example, expression of miR150 in
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megakaryocyte-erythrocyte progenitors leads to a profound bias of differentiation
towards megakaryocytes, and if c-myb is expressed without the 3’UTR there is a
decrease in the formation of megakaryocytes [134]. This is consistent with results
showing that a knockdown of c-Myb expression results in increased
megakaryocyte production [135]. These data suggest that miR150 is a potent
regulator of c-myb and differentiation, however other microRNAs have been
demonstrated to be of equal importance in regulating c-myb.
MiR15a and miR16 are encoded by the dleu2 tumor suppressor locus,
which is regulated by the Pax5 transcription factor, a c-Myb interacting partner
[136]. During levels of high Pax5 activity miR15a/16 are down regulated resulting
in increased c-myb expression. Likewise, high levels of each microRNA
decreases c-myb and A-Myb expression suggesting that some microRNAs
regulate multiple Myb family members [136]. Further analysis has established
that the miR15a/16 promoter is bound by the c-Myb protein and that functional
miR15a can inhibit erythroid and myeloid colony formation [137]. These results
suggest that c-Myb protein plays a critical role in regulating its own expression,
which is important for proliferation, differentiation, and apoptosis. Other
microRNAs such as miR34a are complementary to the c-myb 3’ UTR and recent
studies have identified that miR34a regulates c-myb expression during
megakaryocyte development [138], suggesting that different microRNAs can
promote different cellular processes.
Abnormal regulation of microRNAs has been implicated in numerous
forms of cancer. For example, miR15a is deleted in many tumors. Since many
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miR15a targets are important for cell cycle regulation [139], these results suggest
that loss of miR15a leads to changes in the cell cycle. In contrast, other
microRNAs such as miR30 are up-regulated in a subset of cancers [140]. Thus,
the regulatory pathways affecting microRNAs are complex and deregulation can
occur in the form of deletion, amplification, mutation, and silencing of the genes
via epigenetic marks [141].
Attenuation as a regulator of c-myb transcription

There is differential expression of c-myb in a variety of different cells
during differentiation and changes in c-myb expression can be attributed to
attenuation of transcriptional elongation in B-cells [142]. This attenuation is
mediated by sequences within the first intron of the c-myb gene, which includes a
DNase I hypersensitive region [143]. During differentiation there is a reduction of
protein binding to intron I, correlating with decreased c-myb expression [144].
The intron I region contains binding sites for a number of transcription factors
including AP-1, SP1, and the estrogen regulated P2 protein [144], and in breast
cells the attenuation is relieved in the presence of estrogen [54]. This suggests
that intron I attenuation is regulated by mitotic signals in a cell cycle dependent
manner. Mutation of the intron I region occurs in some colon cancers, which
could lead to the over-expression of c-myb and contribute to transformation
[145]. Thus, a number of transcriptional and post-transcriptional mechanisms are
involved in controlling c-myb expression, and these mechanisms play important
roles in controlling differentiation and proliferation.
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IV. Implications for the regulation of c-Myb during the cell cycle
Myb genes are cell cycle regulated

Stimulation of primary peripheral blood lymphocytes (PBLs) has
demonstrated that c-myb is expressed in a cell cycle dependent manner. c-myb
RNA levels peak in expression during the G1/S transition [146, 147] and protein
expression can be detected slightly later [148]. These changes in expression
level suggest that cell cycle specific mechanisms participate in the induction of cMyb during different phases of the cell cycle. The c-myb gene promoter contains
binding sites for the cell cycle transcription factor E2F [149], which could be one
mechanism for explaining the induction of the c-myb gene during the cell cycle.
The two related proteins, A-Myb and B-Myb, have distinct patterns of
expression during the cell cycle. In hematopoietic cells, expression of B-Myb
mRNA peaks during the G1/S transition and mutation of the E2F binding site in
the B-Myb promoter leads to defective B-Myb gene induction [150]. Both c-myb
and mybl2 (B-Myb) appear to peak in expression during G1/S, but expression of
the A-Myb gene peaks in G0/quiescent hematopoietic cells [22], showing that
each of the myb genes is regulated differently. Interestingly, some cell type
specificity exists, since in vascular smooth muscle cells A-Myb transcription
peaks at the G1/S transition [151]. These data establish that all three MYB
genes are cell cycle regulated.
Regulation of the cell cycle by Myb proteins

Several types of evidence have linked the Myb transcription factors to cell
cycle regulation. For example, other evolutionarily related proteins such as
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drosophila Myb (DMYB), A-Myb, and B-Myb all have documented cell cycle
regulatory roles. Mutated alleles of DMYB have detrimental effects on the cell
cycle [152] and lead to genomic instability [153]. Recent studies have shown that
DMYB is part of the dREAM complex that coordinates specific cell cycle
regulation of target genes, particularly in G2/M [154, 155]. B-Myb is the most
closely related to the Drosophila DMYB gene [156] and B-Myb, but not c-Myb, is
an active component of the Mip/Lin-9 complex, the mammalian ortholog to the
dREAM complex. As part of the Mip/Lin-9 complex, B-Myb regulates genes in a
G2/M specific manner. B-Myb is also required for proper regulation of the mitotic
spindle [157-160] and for inner cell mass formation [161]. These activities appear
to be specific for B-Myb, highlighting the importance of B-Myb in both cell cycle
regulation and differentiation, and demonstrating that different Myb proteins have
completely different functions.
The A-Myb protein is also associated with proper cell cycle progression.
Knockdown of A-Myb leads to an arrest of spermatogenesis and defects in
breast cell development [162, 163]. These tissues undergo a high level of
proliferation suggesting that A-Myb is essential for proliferation in these tissues.
Neither A-Myb nor B-Myb is an established oncogene, although expression of
each has been detected in B-cell lymphoma or breast cancer, respectively [164,
165]. The relative over-expression of A-Myb and B-Myb may reflect the higher
rates of proliferation of the tumor cells compared to the normal tissues.
The importance of c-Myb to cell cycle regulation is less well characterized,
but it may be regulated in a way that is analogous to that of B-Myb. The genes
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encoding several important cell cycle regulators, including Cyclins A1, B1 and
E1, are regulated by c-Myb, at least in some cell types [49, 50, 53]. However,
these genes are induced in different phases of the cell cycle, so if c-Myb is
involved in their regulation, then c-Myb activity or specificity must also be
regulated by the cell cycle. Since c-Myb interacts with Cyclin D1 [51] and with
cyclin dependent kinases CDK4 and CDK6 [52], it is possible that c-Myb
specificity is regulated through a mechanism of cell cycle stage-specific
phosphorylation, similar to the regulation of the Retinoblastoma protein and the
E2F transcription factors [166, 167]. However, cell cycle specific phosphorylation
of c-Myb has not yet been documented. Alternatively, c-Myb may only be an
accessory transcription factor that cooperates with other proteins that are more
specifically regulated. For example, c-Myb could form cooperative complexes
with E2F at specific promoters, in the way it does with C/EBPbeta. The direct
regulation of E2F could recruit c-Myb to specific promoters at different stages of
the cell cycle, making c-Myb more of a passive participant, rather than an active
component of cell cycle regulation.
Conclusions
c-Myb is not an unlikely candidate to alter the proliferation of cells and the
behavior of c-Myb is not completely unique amongst cell cycle controlled
transcription factors. For example, for many years studies with c-myb were
performed in conjunction with c-myc. Many studies demonstrated increased
expression of c-myc was cell cycle dependent and correlated with leukemia [168,
169]. In fact, c-myc displays a similar pattern of expression during erythroid
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differentiation and although c-myc is expressed upstream of c-myb, both
transcription factors are invaluable for proliferation [170]. c-Myc binds to
thousands of different genes, which has left a puzzling scenario as to why c-Myc
binds to a huge portion of the genome, but recent technology has generated data
suggesting that Myc can have an effect upon chromatin structure [171]. The
genome wide targets of c-Myb have yet to be described and there are two
primary hypotheses to describe c-Myb specificity and function. First, c-Myb binds
to a small fraction of genes and those genes are highly dependent upon c-Myb
for activation or secondly, c-Myb binds to a large fraction of genes and plays a
small, but critically important role in activation.
It is likely that c-Myb is not regulated in a similar manner as c-Myc and is
regulated more like cell cycle proteins such as p53 or E2F. The mechanism of
p53 cell cycle control is mediated mostly by MDM2, which facilitates proper
degradation of p53 [172]. A protein counterpart such as MDM2 has not been
discovered, but protein interactions can affect the activity of the protein. On the
other hand, E2F is regulated in a similar manner as p53, but there is an entire
family of these proteins and E2F proteins can affect both proliferation and
apoptosis, which at times appears contradictory [173]. This type of contradiction
is similar to c-Myb’s role during proliferation and differentiation except there are
fewer Myb family members. Although there are fewer c-Myb family members,
alternatively spliced isoforms have distinct activities and different posttranslationally modified subsets of c-Myb have the potential to mediate the
proliferation of cells. Regulation of other proteins could add some insight about c-
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Myb activity during proliferation and differentiation because c-Myb activity could
be mediated through changes in post-translational modifications or protein
interactions. Therefore, it is critical to consider how other transcription factors are
generally regulated during the cell cycle of other cell cycle because similar
factors could regulate c-Myb.
The most highly related transcription factors to compare c-Myb with are AMyb and B-Myb. Evidence suggests that these Myb proteins are cell cycle
regulated. It is established that c-Myb is extensively modified and results with AMyb and B-Myb extend these results by demonstrating that cyclin/CDK
complexes phosphorylate Myb proteins. For instance, A-Myb and B-Myb interact
with cyclin A: CDK2, which leads to phosphorylation of each protein [109, 174].
Phosphorylation of A-Myb leads to a relief of transcriptional inhibition and
phosphorylation of B-Myb increases transactivation. These results with Myb
related partners demonstrate two important results. First, the same complex
interacts with and phosphorylates each Myb protein, which has distinct effects on
Myb activity. Second, cell cycle machinery such as cyclin A/CDK2 can interact
with multiple Myb proteins. This suggests that Myb proteins, including c-Myb can
shuffle from one complex to another throughout the cell cycle (Figure 4). This
could affect specificity and explain how c-Myb can activate both the CCNB1 and
CCNA1 genes. In addition, it is plausible that this shuffling is coordinated
amongst Myb proteins. It was described that B-Myb activates G2/M specific
genes as a component of the dREAM complex, but c-Myb can bind to some of
the same promoters as B-Myb such as CCNB1. In addition c-Myb interacts with
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CCND1/CDK6 suggesting that it may participate in complexes similar to the
dREAM complex to regulate different sets of genes. These results provide
evidence for c-Myb and B-Myb to have some redundant target genes, but
different interacting partners at different phases of the cell cycle (Figure 5).
This chapter has described the hypothesis that c-Myb post-translational
modifications and protein interactions account for changes in c-Myb activity. As
many have shown, there is an extensive regulation of c-myb gene expression
and RNA turnover that is important for our future understanding of c-myb in
cancer formation. A disparity between c-Myb activity and c-myb expression exists
and results suggest that the differential activities of c-Myb, which may appear at
first glance to be antagonizing, actually are due to different sub-populations of
the same protein. Hypothetically these populations could be expressed all of the
time, but only a minute fraction is active or alternatively, and most likely, is that
these populations are formed in response to signaling changes outside of the cell
and post-translational modifications and interacting partners define each subpopulation. Therefore, future experiments that define these sub-populations will
enhance our knowledge and understanding of how c-Myb transforms into an
oncoprotein.
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Figure Legends
Figure 1: Conserved domains in Myb proteins.

All Myb proteins have a conserved DNA binding domain (shaded dark
grey) with a transactivation domain (TAD). The extreme C-termini or negative
regulatory domain (NRD) are known to regulate activity, specificity, and negative
regulation. v-Myb is truncated, but contains regions of conservation (shaded light
grey) and mutated within the remaining portion of the protein (open circles).
Figure 2: c-Myb is actively modified after translation.

A. c-Myb is phosphorylated throughout the protein by a multitude of
different kinases and the C-terminus is SUMOylated and acetylated. These
modifications affect protein interactions and activity. B. c-Myb interacts with
different types of proteins and many of them bind to the DNA binding domain. A
select few such as Pim1 and p300 result in post-translational modifications that
affect activity.
Figure 3: c-Myb sub-populations regulate T-cell development.

c-Myb is essential for proper T-cell development and defects in c-Myb
expression cause different phenotypes in different stages of development. c-Myb
has a wide array of target genes and it is likely that different versions of c-Myb
have different activity and specificity in different stages of development and
different cell types.
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Figure 4: Myb proteins are cell cycle regulated.

Components of the cell cycle such as cyclin/CDK complexes can interact
with all Myb proteins. A-Myb and B-Myb are phosphorylated by different pairs of
cyclin/CDK complexes during the cell cycle. These post-translational
modifications alter Myb activity in a cell cycle dependent manner.
Figure 5: Myb proteins have the potential to compensate for each other.

B-Myb and c-Myb have some redundant functions in myeloid cells and can
both bind to the CCNB1 gene. It is likely that during proliferation, at different
stages of the cell cycle, B-Myb and c-Myb shuffle on and off of the same
promoters in a cell cycle dependent manner.
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Chapter Two: Specificity in the Cell Cycle
The disparity between the level of c-myb expression and c-Myb activity is
a difficult to explain, but characterizing this disconnect is essential to describing
the effect of c-Myb on cancer formation. As discussed, c-Myb activity can change
in single cells types, such as T-cells, depending on the nature of the cell (i.e.
double negative, double positive or single positive). It is plausible that different
sub-populations of c-Myb exist in different subsets of cells and this hypothesis
can be applied to different biological processes. For example, if c-Myb is
constitutively expressed during the cell cycle, then different versions of the c-Myb
protein could account for the differences in c-Myb activity. c-Myb regulates three
cyclin promoters, CCNB1 [50], CCNE1 [53], and CCNA1 [49], and each of these
genes is responsible for regulating a different part of the cell cycle; CCNB1 and
CCNA1 regulate G2/M and CCNE1 regulates S-phase. The function of these
genes and the cyclic regulation of each suggest that if c-Myb regulates their
expression, c-Myb must be constitutively expressed in asynchronous cell
cultures.
We hypothesize that c-Myb protein expression is relatively constant and
although c-Myb half-life is short there is sufficient amounts of protein during all
phases of the cell cycle. We developed a model system to characterize c-Myb
specificity during the cell cycle. We employed flow cytometry to sort cells into
distinct subsets based on DNA content and characterized c-Myb occupancy with
Chromatin Immunoprecipitation (ChIP). These data demonstrate that c-Myb
protein is constantly present during the cell cycle and that specificity/activity are
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dynamic because c-Myb associates with different genes in different subpopulations of cells.
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Summary
The c-Myb transcription factor is a critical regulator of proliferation and stem cell
differentiation, and mutated alleles of c-myb are oncogenic, but little is known
about the activities of c-Myb during the cell cycle. We used fluorescence
activated cell sorting to divide asynchronously growing populations of human
cells into different cell cycle fractions, and then applied chromatin
immunoprecipitation assays to determine the occupancy of c-Myb on the
promoters of known target genes. We found that the specificity of c-Myb is
dramatically different in small subpopulations of cells, for example cells in the
G2/M phase of the cell cycle, than in the bulk population. Our results show that cMyb undergoes dynamic, time-dependent repositioning, regulating different
target genes in specific phases of the cell cycle, and that the specificity of c-Myb
is actively regulated in real time in human cell lines, primary cells and leukemia.

Highlights
•

c-Myb occupancy at cyclin gene promoters is cell cycle dependent

•

c-Myb specificity varies dramatically during different phases of the cell
cycle

•

c-Myb regulates the CXCR4 gene in leukemia cells

43

Introduction
The c-Myb transcription factor is responsible for the proper regulation of
hematopoiesis and proliferation [175]. Inhibition of the c-myb gene blocks
hematopoietic cell differentiation in vitro [46] and leads to a loss of hematopoietic
cells in animals [38]. v-Myb is a truncated mutated derivative of the human c-myb
gene and causes acute myeloid leukemia in chickens and mice [7]. c-myb is
amplified in T-ALL [32] and has been implicated in solid tumors such as breast
[28] and colon [29] suggesting that c-Myb is important for cancer progression.
Treatment of cancer cell lines with antisense oligonucleotides specific for
c-myb decreases proliferation demonstrating that c-myb is essential for proper
proliferation [47, 176]. c-myb is expressed in all proliferating progenitor cells [23]
and has been implicated in the cell cycle regulation of multiple cell types such as
T-lymphocytes and breast cells. For example, c-myb expression peaks at the
G1/S transition of stimulated peripheral blood lymphocytes [146]. These results
suggest that c-myb expression is regulated in a cell cycle dependent manner.
c-Myb protein is expressed during stimulation of peripheral blood
lymphocytes [148] and the activity of c-Myb is linked to the cell cycle. c-Myb
regulates a number of different genes that are essential for cell cycle progression
such as CDC2 [111], CCNA1 [49], and CCNB1 [50] but the mechanism
controlling c-Myb activity at these promoters is unknown.
At least two mechanisms have been described for transcription factor
regulation during the cell cycle. One example is E2F transcription factors, which
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are inhibited during the G1 phase of the cell cycle by bound Retinoblastoma
tumor suppressor protein. In S phase, Cyclin D1/CDK4 phosphorylation of
Retinoblastoma triggers its removal and leads to the activation of E2F target
genes [177]. In contrast, receptor-activated signaling cascades lead to activation
of kinases like Akt, which phosphorylate FOXO transcription factors, leading to
their migration to and sequestering in the cytoplasm and preventing them from
regulating the expression of genes encoding cell cycle regulators [178]. Both of
these examples are ways in which transcription factors change activity or
localization, but not specificity, during the cell cycle.
We set out to monitor the activity of c-Myb and determine whether it
undergoes changes in specificity during the cell cycle. We wanted to study the
regulation of c-Myb under conditions of asynchronous cell growth without cell
cycle arrest agents so we used chromatin immunoprecipitation to follow the
association of c-Myb with different gene promoters in cultures of human cells that
were progressing normally through the cell cycle. This approach allowed us to fix
the proteins to DNA with formaldehyde while the cells were still in the culture
dish, locking in the results before the cells were manipulated in any way. Then
the cells were harvested, sorted into cell cycle stages and used for chromatin
immunoprecipitation experiments. The results show that c-Myb undergoes
dramatic and dynamic repositioning onto different gene promoters during the cell
cycle and suggest that c-Myb regulates the cell cycle by changing specificity in
response to cellular cues.
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Results
Fractionation of Jurkat Cells by Hoechst 33342

The development of Chromatin ImmunoPrecipitation (ChIP) assays for the
detection of c-Myb target genes [179] provided a means to follow the activity and
specificity of c-Myb during the cell cycle. We chose Jurkat T cells, a human cell
line to characterize c-Myb specificity during the cell cycle in which we showed
previously that c-Myb protein interacts with the cell cycle regulatory proteins
CDK4, CDK6 and Cyclin D1 [52], suggesting that c-Myb activity might be
regulated during the cell cycle in these cells. We started by developing a system
to fractionate asynchronously cultured cell populations into different cell cycle
phases based on DNA content. Briefly, asynchronously growing populations of
Jurkat cells were stained with the DNA content dye Hoechst 33342 and
subjected to flow cytometry. Cellular fractions were then subjected to RNA
analysis, protein expression, and ChIP assays. As shown in Figure 1A, Hoechst
33342 is cell permeable and cells stained with this dye show a typical cell cycle
distribution of 60.5% G1, 15.1% S-phase, and 15.5% G2/M. As an initial
confirmation of our sorting procedure we performed expression analysis of the
human CCND1 gene. Figure 1B demonstrates that CCND1 expression is
detected in asynchronous cell populations and the sorted G1 fraction of cells, but
not the S/G2/M fraction. Our endogenous control gene PPIA was detected in all
sorted fractions suggesting that our data with CCND1 accurately reflected cell
cycle distribution. We wanted to verify that c-Myb protein is expressed in each
phase of the cell cycle. To detect c-Myb protein accurately in sorted cells we first
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fixed the cells with formaldehyde as per a ChIP assay then stained and sorted
the cells as described. We used the fixed cells to purify c-Myb protein on a
hydroxyapatite column to select for c-Myb bound to DNA. Briefly, equal cell
numbers of the fixed asynchronously growing cells, the G1 population, or a
mixture of the S + G2/M populations were incubated with pre-equilibriated
hydroxyapatite, washed, decrosslinked, and analyzed using a Western blot with
anti-c-Myb antibodies. c-Myb protein were detected in all the samples,
suggesting that c-Myb protein was both expressed and bound to DNA during the
cell cycle in these cells (Figure 1C).
c-Myb binding oscillates during the cell cycle

We verified that c-Myb is expressed at each phase of the cell cycle so we
performed our sorting procedure followed by ChIP assay to characterize c-Myb
specificity at c-Myb target promoters. We wanted to determine how c-Myb
regulates the cell cycle so we concentrated on CCNB1 and CCNE1, both of
which are documented potential c-Myb target genes [50, 53]. Significant
differences in c-Myb activity/specificity were detected when we performed ChIP
at these target genes with two independent anti-c-Myb antibodies. The 1493
antibody specifically recognizes an epitope upstream of the FAETL domain and
the Ab 1-1 antibody is specific to an epitope in the C-terminal domain (Refer to
Chapter 3 Figure 1). Figure 2A shows the results of ChIP assays performed at
CCNB1, which demonstrated that c-Myb was bound to the CCNB1 promoter in
asynchronous cells, G1 fractionated cells, and G2/M fractionated cells. We used
two different c-Myb-specific antibodies for these experiments, and both
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antibodies detected significant enrichment of the Cyclin B1 promoter in the same
populations. We performed RNA isolation in fractionated cells and detected
slightly higher levels of CCNB1 transcripts in the S/G2/M sample (Figure 2B). In
addition, our RNA expression analysis verified that c-myb transcript was
detectable in G1 and S/G2/M supporting our protein expression data in Figure 1.
We also assessed the association of c-Myb with a binding site that we
identified upstream of the Cyclin E1 promoter (Data shown in chapter 3
Supporting Data). Strikingly, c-Myb was not detectable at this enhancer in the
asynchronous, G1 or S phase fractions, but c-Myb immunoprecipitation strongly
enriched for the Cyclin E1 promoter in the G2/M phase cells (Figure 3A).
Expression experiments showed that CCNE1 mRNA levels correlated with the
presence of c-Myb at the enhancer, since the RNA was only detectable in the
S/G2/M phase sample (Figure 3B), suggesting that c-Myb binding led to
activation of the CCNE1 gene in the S/G2/M phase cells. We presume that the
inability to detect c-Myb at CCNE1 in asynchronously growing cells was due to
the relatively small fraction of G2/M phase cells in the total population. Thus,
these experiments show two important results. First, that c-Myb activity and
specificity appears to be cell cycle regulated, leading c-Myb to bind to and
activate different promoters in different phases of the cell cycle. And second, that
c-Myb activity can vary considerably in different subsets of cells, such as the
G2/M population of Jurkat cells, and that these activities can be masked or go
undetected if only total populations of asynchronously growing cells are
analyzed.
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Ectopically expressed c-Myb is also cell cycle-regulated

The regulation of c-Myb protein expression is quite complicated, involving
changes in c-myb gene regulation [40, 54, 149], including mechanisms that affect
mRNA elongation [142, 144] as well as alternative splicing [118, 120, 180] and
microRNAs that bind in the long 3’-untranslated region to control c-myb mRNA
stability and translation [132, 138]. The c-Myb protein is also known to be posttranslationally modified at numerous positions [88, 96, 99, 103], so there was a
possibility that these modifications could affect antibody binding, artificially
affecting the outcome of the ChIP assays. To test whether these mechanisms
contributed to our cell cycle results, we used lentiviral vectors to generate a
stably transduced derivative of Jurkat cells expressing a FLAG epitope-tagged
version of c-Myb. In these cells, the FLAG-tagged version of c-Myb is
independently expressed from a different promoter, is engineered to react with a
different (anti-FLAG) antibody, and the encoded mRNA lacks the normal 3’UTR
region containing the regulatory microRNA binding sites [37]. Control
experiments showed that the anti-FLAG antibody efficiently immunoprecipitated
the epitope-tagged protein from these cells (Figure 4). We performed the same
fixation-sorting-ChIP assay with the cells expressing the FLAG-tagged c-Myb,
and obtained nearly identical results as with the other antibodies. As shown in
Figure 5A, the FLAG-tagged c-Myb was associated with the Cyclin B1 gene
promoter in the asynchronous, G1 and G2/M phase cells, but was not detectable
in the S phase cells. Similarly, as shown in Figure 5B, the FLAG-tagged c-Myb
only associated significantly with the Cyclin E1 promoter in the G2/M phase cells,
we obtained the same result using two different c-Myb-specific antibodies (Figure
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2 and Figure 3). These results suggest that our ChIP assay results are not due to
differences in antibody efficacy and rule out the possibility that our ChIP assays
were detecting other transcription factors, e.g. the related B-Myb protein, which
has also been shown to regulate the CCNB1 promoter in the G2/M phase of the
cell cycle [157, 159, 160]. Based on all of these results, we conclude that c-Myb
activity and/or specificity change dynamically during the cell cycle, and that
despite being expressed in all cell cycle stages, even when ectopically expressed
from a different promoter, c-Myb associates with different target gene promoters
in different phases of the cell cycle.
Cell cycle mechanisms governing c-Myb specificity are not limited to cyclin gene
promoters

The results described above suggest that c-Myb associates with the
promoters of certain genes, such as CCNB1 and CCNE1, in a cell cycledependent manner. However, it was possible that genes important for cell cycle
regulation were unusual or different than other Myb-regulated genes. To extend
our results we also analyzed the association of c-Myb with the promoters of
genes that, unlike cyclins, are not expected to be cell cycle regulated. We
previously identified the CXCR4 gene as a potential c-Myb target, based on its
activation in microarray assays [21]. CXCR4 is the receptor for the chemokine
Stromal Cell-Derived Factor-1 and its expression correlates with poor prognosis
in several types of leukemia [181, 182]. Over-expression of CXCR4 has also
been demonstrated to increase the proliferation of CD34+ cells and the stem cell
potential of CD34+ cells in re-population assays [183]. In Jurkat cells, we did not
detect c-Myb at the CXCR4 promoter in G1 phase cells, but both of our anti-c-
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Myb antibodies detected c-Myb at the CXCR4 promoter in G2/M phase cells
(Figure 6A). However, only one of the antibodies, our rabbit antiserum 1493,
successfully enriched for the CXCR4 promoter in the S phase cells, suggesting
that the two antibodies detected different forms of c-Myb, or perhaps that the
epitope recognized by monoclonal Ab 1-1 was modified or masked in the S
phase cells. To confirm these results, we again utilized the Jurkat cells stably
expressing FLAG epitope-tagged c-Myb. Using the anti-FLAG antibodies, c-Myb
was detected at the CXCR4 promoter in both the S and G2/M phase cells, but
not in G1 phase cells (Figure 6B). As an independent measure, we used a
double thymidine block to synchronize the Jurkat cells at the G1/S boundary,
then performed ChIP assays at various times after releasing the block. As shown
in Figure 6C, we did not detect c-Myb at the CXCR4 gene promoter in the
blocked cells (time 0), but saw a peak in c-Myb binding at 3 hr, which
corresponded to 50% of the cell in early S-phase, followed by less binding at
later times during a synchronized cell cycle. Thus, c-Myb binding to the CXCR4
promoter changed in a time-dependent manner as the cells progressed through
the cell cycle. Since c-Myb associated with the CXCR4 promoter in S phase,
these results rule out the possibility that c-Myb was in some way inactivated
during S phase, which could have explained the lack of S phase binding to the
CCNB1 or CCNE1 promoters, described above. These results confirm that c-Myb
associates with different genes in different phases of the cell cycle in Jurkat T
cells, and demonstrate how ChIP results can vary when different antibodies are
used. The results also show, quite unexpectedly, that c-Myb only associates with

51

the CXCR4 gene promoter in cells that are actively progressing through the cell
cycle, and not in the G1 cells that make up more than 60% of the cells in the
culture. Thus, the asynchronous population of Jurkat cells contains several
subpopulations of cells that can be distinguished both by stage in the cell cycle
and by the genes that c-Myb is associated with.
Discussion
There is ample evidence that c-Myb is involved in the regulation of
proliferation and differentiation, and that mutated versions of c-Myb affect the cell
cycle [175]. Since c-Myb had been implicated in the regulation of cyclin genes
CCNB1 [50] and CCNE1 [53], which are regulated during the cell cycle, we set
out to determine whether c-Myb activity was also cell cycle-regulated. We found
that c-Myb binds to different promoters in distinct stages of the cell cycle,
suggesting that its specificity was dynamically regulated, allowing it to activate or
repress different target genes in different phases of the cell cycle. This is a
different mechanism than has been described for the E2F proteins, whose
stimulatory and inhibitory family members are regulated through cell cyclemediated changes in interactions with Retinoblastoma protein and the related
pocket proteins p107 and p130 [177, 184]. It is also different than the FOXO
proteins, which become inactivated and sequestered in the cytoplasm after
phosphorylation by kinases like Akt [178]. Unlike E2F and FOXO proteins, c-Myb
remains active throughout the cell cycle, but it interacts with different promoters
at different times. For example, we found that c-Myb is associated with the
CCNB1 promoter in G1, the CXCR4 promoter in S phase, and the CCNB1,
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CCNE1 and CXCR4 promoters in G2/M. Thus, c-Myb does not appear to be
activated or inactivated during the cell cycle. Instead, as the cell cycle
progresses, c-Myb becomes retargeted to different promoters in a time- and
stage-dependent manner. The retargeting of c-Myb also distinguishes it from the
related transcription factor B-Myb (MYBL2), whose ability to activate transcription
is regulated by G2-specific Cyclin A/CDK2 phosphorylation [109, 185] and which
is a component of the LINC complex involved in activation of G2/M specific
genes [157, 159, 160].
The cell cycle regulation of c-Myb is reminiscent of NF-Y, the ubiquitously
expressed transcription factor that binds CCAAT-box promoter elements [186,
187]. NF-Y, which has histone-like subunits, displaces nucleosomes from
multimeric CCAAT-boxes at the promoters it regulates and stimulates histone
acetylation and gene activation [188, 189]. The c-Myb transcription factor is also
involved in chromatin remodeling, via its Myb/SANT domain, which is related to
components of chromatin remodeling complexes [74, 75]. The c-Myb Myb/SANT
domain binds to histone tails and promotes their acetylation, stimulating the
remodeling of chromatin and gene activation [76]. Thus, NF-Y and c-Myb may
share the ability to initiate the remodeling of chromatin and the activation of cell
cycle regulated genes.
A major unanswered question concerns how c-Myb and NF-Y become
targeted to the appropriate promoters at the correct times in the cell cycle. NF-Y
regulates different classes of promoters at different times in the cell cycle, but it is
thought to activate constitutively: the cell cycle-dependent regulation occurs
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through other factors, like E2F, that repress or activate at specific times in the
cell cycle [190]. In contrast, the regulation and specificity of c-Myb appears to be
regulated during the cell cycle and may be linked to its interactions with Cyclin
D1/CDK complexes, since phosphorylation at specific residues could change the
affinity of c-Myb for specific promoters by altering its ability to interact in a
combinatorial fashion with other proteins [56]. Several types of evidence have
shown that the specificity of c-Myb can be affected by mutations [21, 52, 69] and
that c-Myb regulates completely different sets of target genes in different cell
types [21, 80], suggesting that its specificity is controlled by interactions with
other proteins. Our new results suggest that these interactions and the activities
of c-Myb are not only tissue-specific, but also change dynamically during the cell
cycle.
A final question is whether the changing specificity of c-Myb is linked to its
potential oncogenic activity. We have shown that the mutations that render c-Myb
oncogenic also completely change its specificity, leading to the activation of
different sets of target genes [21, 70]. Our discovery of cell cycle specific
changes in c-Myb activity raise the possibility that oncogenic versions of c-Myb
may transform cells by regulating some target genes in the incorrect stage of the
cell cycle, which could stimulate cell cycle progression or inactivate cell cycle
checkpoints. There is evidence that oncogenic versions of c-Myb push
transformed cells through the cell cycle, even in the absence of mitogenic growth
factor signals [191]. There is also a difference in the interactions between Cyclin
D1 and normal or oncogenic versions of c-Myb [51]. Thus, oncogenic versions of
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c-Myb may have altered cell cycle-dependent activities, which could be the key to
their transforming activities.
Experimental Procedures
Cells and Culture Conditions

Human Jurkat T-cells (ATCC TIB152 Manassas, VA) were cultured at
37°/5% CO2 in RPMI + Glutamax medium (Invitrogen, Carlsbad, CA)
supplemented with 10% (v/v) fetal bovine serum (Invitrogen, Carlsbad, CA).
Cell Cycle Analysis

For thymidine block, cells (5X105/ml) were incubated in 2 mM thymidine
for 16 hr, released in fresh medium for 9 hr then blocked again with a second
round of 2 mM thymidine for 16 hr. After release, cells were collected at different
time points and ChIP was performed with anti-Myb 1493 antibodies. For RNA
expression analysis, asynchronous cell cultures were stained with Hoechst DNA
content dye (Invitrogen, Carlsbad CA) and sorted based on DNA content as
described (G1 or S/G2/M populations) [192]. RNA was isolated from equal cell
numbers with RNeasy Kit (Qiagen, Valencia CA) according to manufacturer’s
protocol and reverse transcribed (3 ug) into cDNA template with Reverse
Transcriptase III (Invitrogen, Carlsbad CA). Taqman (Applied Biosystems, Foster
City, CA) real time PCR was used (except for CCNE1, SYBR green was used) to
analyze the expression of c-myb, CCNB1, CCND1, and PPIA. For protein
expression, formaldehyde-fixed proteins were extracted and purified by
hydroxyapatite chromatography as described [193, 194]. Briefly, cells were lysed
in lysis buffer (5M Urea, 2M guanidine hydrochloride, 200mM potassium
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phosphate buffer, and 2M NaCl supplemented with 1µM chymostatin, leupeptin,
antipain, pepstatin-A, 1mM each phenylmethylsulfonyl fluoride and benzamidine),
incubated on pre-equilibriated hydroxyapatite beads (Biorad, Hercules, CA),
decrosslinked at 65° for 5 hours, and precipitated with chloroform: methanol (1:4)
before analysis by Western blot.
Immunoprecipitation

Cultured cells were harvested by centrifugation and washed with
phosphate buffered saline. Cells (1X107 per IP) were lysed in RIPA buffer (50
mM Tris-Cl, pH 7.4, 1% v/v Nonidet P-40, 0.5% w/v deoxycholate, 0.1% SDS,
150 mM NaCl with 1 µM each of chymostatin, leupeptin, antipain, pepstatin-A; 1
mM each of phenylmethylsulfonyl fluoride and benzamidine) for 1 hr on a rocker
at 4° and centrifuged at maximum speed (13000 g) for 10 min in a
microcentrifuge to remove debris. The supernatant (10% of volume) was taken
as input control and the remainder was used for subsequent immunoprecipitation
(IP) with anti-c-Myb (Millipore, Billerica, MA) or anti-FLAG antibodies (Sigma, St.
Louis, MO). Following overnight antibody incubation, protein A/G agarose (30µl)
(Santa Cruz Biotechnology, Santa Cruz, CA) was incubated for 30 minutes at
4°C. The agarose: antibody complexes were harvested by centrifugation and
washed in triplicate with RIPA buffer (50 mM Tris-Cl, pH 7.4, 1% v/v Nonidet P40, 0.5% w/v deoxycholate, 0.1% SDS, 150 mM NaCl with 1 µM each
chymostatin, leupeptin, antipain, pepstatin-A; 1 mM each phenylmethylsulfonyl
fluoride and benzamidine). Samples were resuspended in 5X SDS-PAGE sample
buffer and analyzed by Western blot analysis with anti-c-Myb [66].
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Chromatin Immunoprecipitation

Standard methods were used [195, 196] except chromatin was sheared in
a 200 µl volume of 50 mM Tris pH 8.0 (Sigma, St. Louis, MO) by adding 40 units
of Micrococcal nuclease (USB, Cleveland, Ohio) for 10 min at 37°C. Adding
EDTA to 10 mM stopped the reaction and cells were lysed in 1% v/v SDS. Equal
aliquots were subjected to immunoprecipitation with anti-Myb 1493 immune
serum (10 µl) or anti-Myb monoclonal 1-1 antibodies (Millipore, Billerica MA) or
control non-immune serum (10 µl) for 24 hr. Anti-Myb 1493 is a rabbit polyclonal
developed against a peptide HQGTILDNVKNLLEFAE. Primers used for QPCR
reactions using SYBR green (Biorad, Hercules CA) are listed in Supplemental
Table 1 (Chapter 2).
Myb Lentivirus Vector

The cDNA encoding an N-terminal FLAG-tagged human c-Myb [21] was
cloned into the unique PacI site of the pHR IRES GFP lentiviral vector (kindly
provided with packaging vectors by Dr. Bruce Bunnell, Tulane University) directly
downstream of the human elongation factor 1 alpha promoter. Viral particles
were produced by calcium phosphate transient transfection of 293 FT cells
(Invitrogen, Carlsbad CA) along with the lentiviral packaging plasmid delta 8.9
and the pMD.G plasmid expressing the vesicular stomatitis virus glycoprotein.
Cell culture supernatant was collected twice in 24 hr intervals post transfection
and viral supernatant was concentrated by ultrafiltration using an Ambion
Ultracell 100 kDa NMWL filter unit (Millipore, Billerica MA). Jurkat cells were
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transduced in the presence of 8 ug/ml of polybrene (Sigma, St. Louis MO) and
GFP+ cells were recovered by cell sorting.
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Figure Legends
Figure 1. Accurate fractionation of asynchronous cultures

(A) Jurkat cell cycle analysis. Cell cycle histogram of a representative
culture of Jurkat T cells progressing through the cell cycle. The cells were fixed
with formaldehyde, stained with Hoechst 33342, analyzed by flow cytometry and
sorted into G1, S, or G2/M populations. The fraction of cells in each cell cycle
phase is indicated at the top. (B) Expression of CCND1. cDNA was prepared
from Jurkat cells sorted into G1 or S/G2/M cell cycle fractions. The samples from
asynchronous (Asyn), G1 or S/G2/M fractions were analyzed by semi-
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quantitative PCR with CCND1 and PPIA specific primers. (C) Expression of cMyb protein. Formaldehyde fixed Jurkat cells were sorted into G1 or S/G2/M
fractions. Equal cell numbers were used to isolate protein and select for protein
bound to DNA through a hydroxyapatite column. Western blot with anti-c-Myb
antibodies detected c-Myb in each fraction.
Figure 2. Cell cycle regulation of the CCNB1 promoter.

(A) ChIP analysis with sorted fractions. ChIP assays with anti-c-Myb 1493
antibodies or anti-c-Myb ab-1-1 were performed with chromatin from
formaldehyde fixed and stained Jurkat cells. QPCR was used to measure
enrichment of the CCNB1 promoter. Error bars show standard deviation of
triplicate QPCR reactions. (B) Levels of CCNB1 mRNA in sorted G1 or S/G2/M
fractions of cells. cDNA was prepared from sorted Jurkat T-cells and the
normalized RNA level of CCNB1 and c-myb were measured by Taqman real time
PCR. Error bars show standard deviation of triplicate QPCR reactions.
Figure 3. Regulation of CCNE1 is cell cycle dependent.

(A) ChIP analysis at CCNE1. ChIP assays with anti-c-Myb 1493
antibodies or anti-c-Myb ab-1-1 were performed with chromatin from
formaldehyde fixed and stained Jurkat cells. QPCR was used to measure
enrichment of the CCNE1 promoter. Error bars show standard deviation of
triplicate QPCR reactions. (B) Levels of CCNE1 mRNA in sorted G1 or S/G2/M
fractions of cells. cDNA was prepared from sorted Jurkat T-cells and the
normalized RNA level of CCNE1 was measured by Sybr green based real time
PCR. Error bars show standard deviation of triplicate QPCR reactions.
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Figure 4. Expression of Flag-tagged c-Myb in Jurkat cells.

Whole cell extracts from Jurkat cells stably expressing FLAG epitopetagged c-Myb were immunoprecipitated with anti-FLAG or anti-Myb 1-1
antibodies. Proteins (input or immunoprecipitated) samples were analyzed by
Western blot.
Figure 5. Cell cycle regulation of ectopically expressed, epitope-tagged c-Myb

Stably-transduced Jurkat cells expressing FLAG epitope-tagged c-Myb
were fixed and sorted and equal numbers of cells from the asynchronous (Asyn)
population or the G1, S or G2/M cell cycle fractions were subjected to ChIP
assays as described in Figure 1, using anti-FLAG or IgG (control) antibodies.
QPCR assays were used to measure the enrichment of the (A) CCNB1 and (B)
CCNE1 promoters. Error bars show standard deviation from triplicate QPCR
reactions.
Figure 6. c-Myb cell cycle specificity is not limited to cyclin genes

Jurkat cells (A) or Jurkat cells stably expressing FLAG epitope-tagged cMyb (B) were fixed, sorted into cell cycle fractions and chromatin was prepared
from equal numbers of cells from the G1, S or G2/M fractions and subjected to
ChIP assays as described in Figures 2 and 3. QPCR assays were used to
measure enrichment of known c-Myb binding sites in the CXCR4 promoter. The
results in panels (A) and (B) were obtained using anti-Myb antibodies 1493 and
1-1, or anti-FLAG antibodies, respectively. (C) Jurkat cells were synchronized
with a double thymidine block then samples were collected for ChIP using antiMyb 1493 antibodies at various times after release. QPCR assays were used to
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measure enrichment of the CXCR4 promoter at time points from 0 to 24 hours.
Error bars show standard deviation of triplicate QPCR assays. Each sample is
normalized to IgG control.
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Supplemental Table 1: Real time PCR primer pairs
Name

Forward Primer

Reverse Primer

CCNB1

TTGTGCCCCACCTTAAT

CATGTTGATCTTCGCCTTATT

+717 to +837

CCNE1

GGCCCCCTCCTCTTCTAGTA

CAGGTCCTCAAAGGCGTCTTA

-4524 to -4327

CXCR4

GCACCTGACCCTAGTGATGCT

TTCAGGAGGTAAAAGGAGTAAAGA

-442 to -525

c-Kit

GCGGTGCCAGGAGCTCCTAA

CTCCCCAGACAATAAAGGTCGACT

-444 to -772

GAPDH

GTGCAGGAGTTCATGACCAAC

CACCTGGGCTAGAGTAC

-245 to -425

CCNE1-R

CTGGAGGTGGCTGGTGTACT

CCATCCTTCTCCACCAAAGA

N/A

PCR

AGTTAATTAACCACTGCTTACTGGCTTATCG

AGTTAATTAACAACAGATGGCTGGCAACTA

N/A

Clone

Supplemental Table 2: Taqman PCR probes
Gene Name
c-myb
PPIA (20X)

Catalog Number
Hs00193527_m1
4333763T

CCNB1

Hs00259126_m1

CCND1

Hs00277039
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Location

Dynamic changes in c-Myb specificity: Potential Mechanism for
Oncogenesis
Until recently it has been difficult to characterize c-Myb specificity in
different cell populations, but we have utilized well established techniques such
as staining by DNA content, ChIP, and flow cytometry to describe the
repositioning of c-Myb from one promoter to the another in a cell cycle dependent
manner. These data demonstrate that c-Myb specificity and activity are dynamic
and different sub-populations of cells exist in a single culture condition. These
results imply that some activity is hidden or undetectable if fractionation of cells is
not performed and it is plausible that this hypothesis can be expanded to the
differentiation process, for instance, differentiation is characterized by cell
surface markers, it is unclear if cells consistently expressing one surface marker
are all in the same cell cycle phase. Therefore, in order to characterize all subpopulations of c-Myb we must continue to refine techniques such as ChIP and
flow cytometry based sorting.
Identification of target genes in normal primary bone marrow is essential.
We have demonstrated that c-Myb repositions in a cancer cell line, but this
mechanism may be different in primary cells. If repositioning becomes
deregulated and G1 specific genes are activated by c-Myb during G2/M, the cell
could push through cell cycle checkpoints and become tumorigenic. It is likely
that changes to the regulatory domain of c-Myb (C-terminal domain) such as
truncation or deletion could affect specificity in a cell cycle dependent manner
because structural changes affect proliferation. However, we have not uncovered
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the mechanism that determines where c-Myb binds and how long it binds there.
We can only suggest that the wide array of post-translational modifications and
protein interactions c-Myb undergoes provide a means of regulating specificity in
a very time dependent manner.

70

Chapter 3: Changes in c-Myb activity during proliferation
c-myb is expressed in epithelial cells and is deregulated in colon cancer,
breast cancer, and lung cancer [28, 29, 35], which suggests that c-Myb regulates
proliferation or differentiation of these cells. Epithelial cells, such as estrogen
positive breast cancer cell lines, offer a unique approach to study the role of cMyb in proliferation because c-Myb is highly associated with estrogen receptor
status [31] and treatment of cells with estrogen relieves a block in c-myb
transcription elongation [54]. The level of c-myb RNA can be manipulated by
withholding estrogen thereby synchronizing cells and initiating cell cycle
progression with exogenous estrogen treatment. This system allows for the
characterization of c-Myb activity during proliferation and since these cells are
highly synchronized and therefore, represent a specific subset of cells it is
possible to identify c-Myb sub-populations.
These data in MCF-7 cells, an estrogen receptor positive cell line support
the hypothesis that protein interactions change while c-Myb is bound to target
genes. We have used two independent antibodies to identify genome wide target
genes by ChIP on chip (ChIP on a promoter tiling array) and characterized c-Myb
activity during different stages of epithelial cell proliferation after estrogen
stimulation. We found that antibodies specific to different regions of the c-Myb
protein have different detection capabilities in different growth conditions even
though a substantial amount of c-Myb is expressed and bound to specific target
genes. Our data suggest that protein interactions mask c-Myb epitopes in a
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growth dependent manner and furthermore, c-Myb does not bind to the same
genes in estrogen deprived cells when c-Myb protein is highly expressed.
Author Contributions
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assays, whole genome amplification, ChIP on chip with two independent Myb
and H3K4me2 antibodies, data analysis, time course experiments, RNA
expression of time course and knockdown and helped write the manuscript. FL
developed the CXCR4 reporter construct and performed luciferase assays in
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Summary
c-Myb is a transcription factor that regulates proper hematopoiesis. While
truncated derivatives are oncogenic, the characterization of existing endogenous
c-Myb sub-populations with distinct activities is yet to be explored. Several
studies have demonstrated that c-Myb interacts with a wealth of proteins such as
p300/CBP, PIM1 kinase, and Pin 1 isomerase and many of these interactions are
associated with post-translational modifications. These modifications occur in
conserved regions and presumably account for differences in the activity of cMyb and its viral counterpart v-Myb. We performed Chromatin
Immunoprecipitation (ChIP) assays with antibodies specific for two highly
conserved domains in the C-terminus to determine if these domains are
associated with increased c-Myb activity. These domains were masked during
estrogen stimulation in an opposing fashion suggesting that c-Myb activity is
dependent on the availability of specific conserved domains.

Keywords

c-Myb activity, ChIP, estrogen, MCF-7 cells
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Introduction
v-myb is a viral transforming oncogene derived from the cellular protooncogene, c-myb. v-Myb is encoded by a retrovirus that induces acute leukemia
in chickens and transforms immature hematopoietic cells in tissue culture [7,
197]. Both c-myb and v-myb are transcription factors that regulate gene
expression and c-myb is expressed in a variety of different tissues including
breast, colon, endothelial, and hematopoietic cells. The role of c-myb in
hematopoiesis has been well characterized and deletion of the c-myb gene
results in an embryonic lethal phenotype due to defects in erythropoiesis [38].
More recently c-myb has been associated with duplication or translocation in
pediatric T-cell acute leukemia (T-ALL) [32].
Ectopic over-expression of c-Myb or v-Myb by adenovirus has
demonstrated that these two Myb proteins regulate distinct sets of endogenous
genes [21]. Similar experiments with two highly related proteins, A-Myb and BMyb, have demonstrated that this phenomenon is not restricted to truncated and
mutated proteins [80]. These data suggest that regions outside of the highly
conserved DNA binding domain affect activity of Myb proteins.
The Myb family of proteins has a highly conserved DNA binding domain,
but their C-termini differ suggesting that while these proteins bind to similar DNA
sequences, they are regulated by their own unique C-terminus. For example, vMyb is truncated at the N and C-termini and contains eleven point mutations
[102, 104, 198]. These deleted and mutated regions in the C-terminus have been
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shown to affect the activity of v-Myb. In a similar fashion, modifications to the cMyb protein can affect binding affinity and activity. The c-Myb protein is
extensively modified by phosphorylation of the N-terminus, acetylation of the Cterminus and SUMOylation during stress [90, 96, 99]. In each case of posttranslational modification, changes in DNA binding, protein stability, and protein
interactions have been confirmed [68, 98, 106]. For example, c-Myb and v-Myb
have similar DNA binding domains, but only c-Myb activates the chicken mim-1
gene. In vitro transfection assays have demonstrated that both c-Myb and v-Myb
are able to bind to the mim-1 promoter [1, 55], but activation of the mim-1 gene is
dependent on the interaction of c-Myb with the chicken NF-M protein. v-Myb is
unable to interact with and therefore lacks the ability to activate endogenous
mim-1 [56, 199].
These results suggest that post-translational modifications and protein
interactions exists in regions not previously characterized and can affect the
interpretation of certain types of experiments. Recently, Chromatin
Immunoprecipitation (ChIP) has provided the transcription factor field with
technology to determine endogenous binding sites. One potential limitation of this
technique is that changes in epitopes due to formaldehyde fization can affect the
outcome of the experiment because formaldehyde fixation will fix protein
interactions as well as DNA: protein interactions. For example, protein
interactions with Pin 1 isomerase and p100 are dependent upon posttranslational modifications such as phosphorylation. During formaldehyde
fixation, Pin1 may be fixed to the c-Myb C-terminus masking specific antibody
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epitopes [87, 198]. Other interactions with proteins such as p100 occur in the cMyb DNA binding domain. These interactions along with many others would
mask the Myb DNA binding domain in a ChIP assay. To overcome this potential
limitation we utilized two independent antibodies, which recognized two
independent domains to characterize the affect of protein domains, epitope
changes, and c-Myb sub-populations on c-Myb activity in MCF-7 breast cancer
cells. Our results suggest that c-Myb domains are masked in an estrogen
dependent manner and the masking of these domains is associated with
increased c-Myb activity.

Results
CXCR4 is a c-Myb target gene

Gene expression profiles of MCF-7 cells expressing c-Myb or the
oncogenic variant v-Myb originally identified CXCR4, which encodes the receptor
for the chemokine SDF-1, as a potential Myb target gene [21]. Both c-myb and
CXCR4 have been previously described as estrogen-inducible genes [54, 200].
Therefore, it seemed plausible that estrogen regulation of c-Myb could be
responsible for subsequent activation of the CXCR4 gene. The promoter region
of the human CXCR4 gene contains multiple potential c-Myb binding sites
(Figure 1B), and when the promoter was introduced upstream of a luciferase
reporter gene it was activated modestly by co-expression of c-Myb and more
dramatically by co-expression of v-Myb (Figure 1C), suggesting that both c-Myb
and v-Myb can bind and activate the CXCR4 promoter. These results mimic
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those obtained with the endogenous gene, which was more strongly activated by
v-Myb than c-Myb [21], suggesting that the CXCR4 gene is regulated by c-Myb.
CXCR4 and c-Myb are regulated by growth stage

To establish the link between estrogen regulation of c-Myb expression and
the subsequent regulation of CXCR4, we turned to MCF-7 cells, a widely-used,
estrogen-dependent mammary tumor cell line that can be growth-arrested in
estrogen-depleted medium, then stimulated by adding back estrogen [54, 200]. In
a time-course experiment, we found that estrogen stimulation caused both c-myb
and CXCR4 RNAs to increase about 3-4 fold relative to the estrogen-deprived
cells by 6 hr (Figure 2A). The stimulation increased to 6-8 fold by 24 hr, but
remained well above the basal level even in cells that were allowed to reach high
cell density (Confl.). Thus, c-myb and CXCR4 genes were induced with similar
kinetics, consistent with the hypothesis that they were regulated by similar
mechanisms.
Interestingly, a Western blot showed that c-Myb protein levels were fairly
constant in all the samples, although there was some accumulation of a fastermigrating form of c-Myb, especially in the cells that had been stimulated by
estrogen for 24 hr (Figure 2B). This suggests that c-Myb protein is fairly stable
and remains expressed at similar levels in MCF-7 cells, despite estrogen-induced
changes in c-myb mRNA levels.
Next, we used a Chromatin Immuno-Precipitation (ChIP) assay to
determine whether c-Myb was directly binding the CXCR4 gene promoter.
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Briefly, MCF-7 cells that were deprived of estrogen, stimulated for 24 hr or
allowed to reach high cell density (Figure 2C) were fixed with formaldehyde and
the chromatin complexes were immunoprecipitated using control non-immune
IgG or two different anti-c-Myb antibodies, 1-1 or 1493, which recognize different
epitopes in the c-Myb protein (see Figure 1A). Both of these antibodies have
been highly characterized and are specific for c-Myb (data not shown,
demonstrated by Dr. Fan Liu). The immunoprecipitated chromatin complexes
were then assayed for the enrichment of the CXCR4 promoter, or control
promoters, using quantitative real-time PCR (QPCR) assays.
Unexpectedly, the two different anti-Myb antibodies gave completely
different results in the ChIP assays. Neither antibody detected c-Myb at the
CXCR4 promoter in the estrogen-deprived cells (Figure 2D), suggesting that the
ability of c-Myb to associate with the CXCR4 promoter is somehow inhibited by
estrogen-deprivation, despite the constant levels of c-Myb protein in the cells
(Figure 2B). The monoclonal 1-1 antibodies, which recognize an epitope from
exon 11 in c-Myb, enriched for the CXCR4 promoter about 8-fold (Figure 2D,
gray bars), but only in the estrogen-stimulated cells and not in the confluent cells.
In contrast, the 1493 antiserum (Figure 2D, black bars), which was raised against
a peptide from exon 9 in c-Myb, strongly enriched for the CXCR4 promoter in the
confluent cells, but not in the estrogen-stimulated cells. These results differ
markedly from our experience using the two antibodies in other cell types, such
as hematopoietic cells, where the two antibodies give nearly identical results in
ChIP assays (AMQ, JPO and SAN, submitted, Chapter 2). The results suggest
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that post-translational modifications, conformational changes or protein-protein
interactions were producing two different populations of c-Myb protein at the
CXCR4 promoter, one of which was recognized only by the 1-1 antibody in
estrogen-stimulated cells, and a different fraction that was recognized only by the
1493 antiserum in the confluent cells. Thus, there appeared to be a switch in the
c-Myb protein associated with the CXCR4 promoter, triggered by the different
growth conditions, which resulted in the ability to be detected by only one or the
other antibody.
Growth conditions also affect FLAG-c-Myb binding the CXCR4 promoter

The results described above suggested that growth conditions affected the
association of c-Myb with the CXCR4 promoter and/or the ability of individual
anti-Myb antibodies to recognize c-Myb associated with the promoter. In order to
have an independent means of measuring whether c-Myb was bound to the
CXCR4 promoter in the confluent and estrogen-stimulated cells, we generated a
stably transfected variant of MCF-7 cells expressing a FLAG epitope-tagged
version of full-length c-Myb. As shown in Figure 3A, anti-FLAG antibodies
efficiently immunoprecipitated the FLAG-tagged c-Myb protein, which ran slightly
higher than the endogenous c-Myb protein in an SDS PAGE Western blot. To
test specificity, we performed a ChIP assay on the FLAG-Myb MCF-7 cells and
compared the ability of the anti-FLAG antibodies to enrich for the CXCR4
promoter compared to two non-specific regions of the genome that did not
contain Myb binding sites. As shown in Figure 3B, the anti-FLAG antibodies
efficiently enriched for the CXCR4 promoter that contains multiple c-Myb binding
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sites, but did not enrich other regions of the CXCR4 gene (NS-1) or a nonspecific control region from the MAT2A gene promoter (NS-2) [201]. Thus, the
ectopically expressed, FLAG-tagged c-Myb protein associated with the same
Myb binding site in the CXCR4 promoter as the endogenous c-Myb protein, and
was efficiently immunoprecipitated by the anti-FLAG antibodies.
Next, we repeated the experiment described in Figure 2D, this time using
anti-FLAG antibodies to see if FLAG-tagged c-Myb was associated with the
CXCR4 promoter in the three different growth conditions. As shown in Figure 3C,
immunoprecipitation with anti-FLAG antibodies gave little to no enrichment of the
CXCR4 promoter in the estrogen-deprived cells, suggesting that c-Myb was not
bound to the promoter under those growth conditions. In contrast, anti-FLAG
resulted in a modest, 5-fold enrichment of the CXCR4 promoter in the stimulated
cells, and over 90-fold enrichment in the confluent cells. Thus, the results using
FLAG antibodies mimicked the results obtained with the 1-1 antibodies in the
estrogen-stimulated cells, and mimicked the results obtained with the 1493
antibodies in the confluent cells. Overall, there appeared to be quantitative
differences in the amount of c-Myb bound to the CXCR4 promoter in the different
conditions. In addition, there appeared to be a switch in c-Myb which affected the
accessibility or availability of the epitopes recognized by the two different
antibodies in the stimulated vs. confluent cells.
Global assays detect additional c-Myb target genes in MCF-7 cells

The results we observed with the CXCR4 gene were intriguing, but we
needed to identify additional Myb-regulated genes in MCF-7 cells in order to
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determine whether the growth condition-induced switch in the c-Myb epitopes
was a general or gene-specific phenomenon. To accomplish this, we performed
whole genome chromatin immunoprecipitation coupled with analysis on promoter
tiling arrays (ChIP on chip) to identify additional c-Myb target genes. Briefly, DNA
purified from chromatin complexes immunoprecipitated by the two different antiMyb antibodies (1493 or Ab1.1) or a control IgG antibody were amplified, labeled
and hybridized to Affymetrix Promoter Tiling arrays with probes spaced at 35 nt
intervals around the promoters of approximately 25,000 human genes. This
approach identified several thousand statistically significant (p < 1x10-5) c-Myb
binding sites enriched by one or more of the antibodies in confluent or estrogenstimulated cells (see Supporting Data), including previously described c-Myb
target genes CCNB1, CCNE1, CXCR4, KIT, MYB and MYC and other genes that
have not been previously identified as Myb-regulated genes, including ELK4,
EPB41, JUN, KLF4, NANOG and SND1. Although we will not present a detailed
analysis of the ChIP on chip results here (See Supporting Data), the complete
data set is available from the NCBI GEO database (accession GSE18706).
We performed two types of experiments to confirm that these putative
target genes were regulated by c-Myb. First, we measured the expression levels
of the target gene RNAs following estrogen deprivation, stimulation by estrogen
for 6, 12 or 24 hr, or in cells that were allowed to become confluent. As shown in
Figure 4A, estrogen led to strong activation of the CCNB1, JUN and KLF4 genes,
but not the EPB41 gene, although the kinetics of activation differed somewhat for
different genes. Second, we tested whether knocking down the expression of c-
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Myb would also lead to knockdown of the target genes. We transduced MCF-7
cells with a previously published retrovirus encoding a doxycycline inducible
short hairpin RNA directed against c-myb [54]. Briefly, transduced cells
(scrambled or MYB shRNA) were treated with doxycycline for 24 hr, RNA was
harvested and real time PCR was used to measure the relative expression of cmyb, CCNB1, CXCR4 and JUN. Western blots verified that after 24 hr of
doxycycline induction c-Myb protein was significantly reduced (Data not shown,
John O’Rourke). As shown in Figure 4B, c-myb RNA levels decreased to less
than 50% of normal and gene expression for JUN, CCNB1, and CXCR4
decreased to 14%, 57%, and 27% of normal, respectively. The scrambled control
shRNA did not cause a significant reduction in c-myb expression and had no
effect on the levels of c-Myb target gene RNAs (Figure 5B). These results
suggest that c-Myb is likely to bind and activate the promoters of these genes
after estrogen stimulation.
Estrogen stimulation induces a switch in c-Myb

Our ChIP assays for the CXCR4 promoter (Figure 2) suggested that
estrogen stimulation induced a switch in c-Myb, such as conformational changes
or post-translational modifications, which affected interactions with the two
different anti-Myb antibodies. We next tested whether the switch could also be
detected on the additional promoters identified through ChIP on chip assays (See
Supporting Material). Briefly, we performed ChIP assays with chromatin purified
from cells that had been estrogen deprived, stimulated for 24 hr or allowed to
reach confluence. We performed parallel assays with both anti-Myb antibodies:
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1-1 and 1493. As shown in Figure 5A, the 1-1 antibodies, which only detected cMyb at the CXCR4 promoter in estrogen-stimulated cells, also only detected cMyb at the EPB41, CCNB1 and KLF4 promoters in the stimulated cells, but not in
deprived or confluent cells. However, the 1-1 antibodies did detect c-Myb at the
JUN promoter in confluent cells, but at about 10-fold lower levels than the very
high enrichment it produced in the stimulated cells. As described above for the
CXCR4 promoter, the 1493 antibodies gave the opposite result (Figure 5B),
enriching for the JUN, CCNB1 and KLF4 promoters only in the confluent cells,
but not in the estrogen deprived or stimulated cells. The exception was the
EPB41 gene, since 1493 antibodies did detect c-Myb at that promoter in both the
stimulated and confluent cells. As a further control, we repeated this experiment
using the MCF-7 cells stably transduced with a FLAG-tagged version of c-Myb.
As shown in Figure 5C, FLAG-c-Myb was detected at levels 4- to 10-fold above
background at the JUN, EPB41, CCNB1, and KLF4 gene promoters in both
stimulated and confluent cells, but not in the estrogen deprived cells. Taken
together, these results suggest that c-Myb is present at all of these promoters in
both the stimulated and confluent cells. However, a switch of some sort occurs in
c-Myb, making it accessible to the 1-1 antibodies only in the stimulated cells and
to the 1493 antibodies only in the confluent cells.
The c-Myb switch is associated with global epigenetic changes

The results described above suggested that our use of two different antiMyb antibodies had exposed a switch in c-Myb that was triggered in MCF-7 cells
grown in different conditions, and that the switch affected c-Myb on multiple,
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perhaps many target genes. We turned to a genome wide epigenetics assay to
determine how global these changes were, and how many genes might be
affected by the switch that we had detected. We performed ChIP on chip with
antibodies specific for Histone H3 lysine 4 dimethyl (H3K4me2), which marks
genes that are either primed for activation or that are actively being transcribed,
and compared chromatin from cells that had been estrogen deprived then
stimulated for 24 hr, or had been allowed to become confluent. We found
dramatic changes in the number and locations of the H3K4me2 marks in the
stimulated vs. the confluent cells, and the differences were gene specific.
Examples of four types of genes that were found to harbor these marks are
shown in Figure 6A. The CCNB1 gene had the H3K4me2 mark in both stimulated
and confluent cells. In contrast, the CCNE1 gene, which is usually only
expressed during S phase, only had this histone mark in the stimulated cells, and
not in the confluent cells. In contrast, the SND1 gene, which encodes a Mybbinding co-activator protein, was only marked in the confluent cells. The estrogen
receptor-regulated GREB1 gene [202] is representative of many genes that
accumulated H3K4me2 marks in the confluent cells. There were also many
genes that did not have the histone mark in either cell type.
A striking result comes from the Venn Diagram analysis, shown in Figure
6B. Of the nearly 2700 statistically significant H3K4me2 enriched sites detected
in the stimulated cells, less than half (1114) were also detected in the confluent
cells. In addition, more than 10,000 new H3K4me2 sites were detected in the
confluent cells. The number of H3K4me2 sites is very large in the confluent cells
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because many genes, like GREB1, had two or more detectable sites in those
cells. Nevertheless, it is clear that there are major differences in the epigenetic
patterns in the stimulated and confluent MCF-7 cells.
We also analyzed the overlap between promoters that had the H3K4me2
mark and also were enriched by the two different anti-Myb antibodies in the two
different growth conditions. As shown in Figure 6C, more than 80% of the
promoters detected by the 1-1 antibodies in the stimulated cells also had the
H3K4me2 mark, indicating that they were primed for activation or already actively
transcribed, but less than 20% of the cells detected by the 1-1 antibody carried
the histone mark in the confluent cells. The 1493 antibodies again gave the
opposite result. Only about 20% of the promoters detected by the 1493
antibodies were also positive for the H3K4me2 mark in the stimulated cells, but
more than 60% of the c-Myb target genes detected by the 1493 antibodies in the
confluent cells also had the H3K4me2 activation mark. Thus, the 1-1 antibody
preferentially detects the c-Myb target gene promoters carrying the H3K4me2
mark in the stimulated cells, and the 1493 antibodies preferentially detect those
genes in the confluent cells. Taken together, these results suggest that the two
different c-Myb antibodies detect different sub-populations of c-Myb protein that
are bound to different populations of target gene promoters in the two different
growth conditions. We conclude that MCF-7 cells contain two populations of cMyb protein: one population, recognized by the 1-1 antibodies, which is
associated with active genes or genes that are primed for activation in estrogenstimulated cells, and a second population, recognized by the 1493 antibodies,
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which is associated primarily with genes that are primed for activation in
confluent cells.
Discussion
These data demonstrated that two highly conserved domains (1493 and
Ab1-1 domain) are masked during different phases of estrogen stimulation.
Furthermore, the loss of accessibility of the 1493 domain can be associated with
increased expression of a number of genes including CXCR4, a gene linked to
distant metastasis in breast cancer [203]. This is the first report establishing that
c-Myb activity rather c-myb expression is affected by the presence and absence
of estrogen. Previous work has analyzed the relative expression of c-myb during
estrogen and tamoxifen stimulation, but has not characterized the c-Myb protein
[54, 200]. Importantly, we have demonstrated that although the expression level
of the c-myb gene is dependent upon the presence of estrogen, the amount of cMyb protein is not affected by estrogen treatment suggesting that there is a
discrepancy between c-myb expression and c-Myb protein availability. However
we cannot determine the function of the c-Myb protein in deprived cells given the
lack of target genes identified in this condition.
It is possible that we uncovered this switch because c-Myb binding is
dynamic and is displaced as cells are stimulated by estrogen, but our data using
FLAG tagged c-Myb suggests that c-Myb is bound to genes in both conditions
and that the domains associated with 1493 immune serum and Ab 1-1 are
masked in an estrogen dependent manner. This masking is not solely reliant on
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changes to the cell cycle because deprived cells do not demonstrate enrichment
with the FLAG antibody. The observation that FLAG antibodies bind to each
promoter during both cellular confluence and estrogen stimulation, but not
estrogen deprivation suggests that the domains recognized by each antibody
undergo some degree of epitope masking. This epitope masking might occur
through post-translational modifications and protein interactions (Figure 7) since
c-Myb interacts with a number of different cofactors such as CBP/p300 [96].
Furthermore, the switch in epitopes from 1493 to Ab 1-1 is critical for activation of
a number of genes, which suggests that the Ab 1-1 region is associated with
active genes during estrogen stimulation. However, the availability of the 1493
region is associated with H3K4me2 demonstrating that this domain is associated
with open chromatin, but not associated with an increased rate of transcription as
is the Ab 1-1 population was.
Transcription factors such as c-myc bind to thousands of genes and play
critical roles in chromatin remodeling [171]. It is highly likely that c-Myb is
important for chromatin remodeling since it binds to nearly 1/3 of the genome and
has been associated with chromatin in previous work [204]. This role in
chromatin-remodeling maybe highly conserved since Drosophilia Myb also binds
to a large portion of the fly genome [205].
Estrogen treatment altered c-Myb epitopes during ChIP assays. This
result corresponds with previously published data suggesting that c-Myb binds to
the Stat5a promoter in a progesterone dependent manner [206]. These data
suggest that c-Myb is subject to modifications in surface accessible domains that
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influence protein interactions. Moreover, domains such as the FAETL domain
have been demonstrated to affect Myb transactivation [207]. The epitope
recognized by the 1493 antibody is slightly upstream of this region. Although
these data correspond well with previously published studies, the 1493 domain
has not previously been shown to be modified and does not correspond to known
sites of interaction with modifying enzymes [96, 208]. However, this region is
surface accessible during cellular confluence and is highly conserved between
chickens, mice, and humans. These data identify a novel domain, whose
availability is directly affected by estrogen and is important for c-Myb activity in
MCF-7 cells.
Finally, our ChIP on chip results revealed a number of target binding
regions and multiple different types of target genes (RNA binding, kinases, etc.).
We confirmed these targets with primary ChIP and FLAG tagged versions of the
c-Myb protein. In addition most of the targets we analyzed have identified Myb
response elements (MRE) within the binding region, but we have also shown that
c-Myb binds to approximately 1/3 of the genome. This is consistent with what has
been documented for other transcription factors such as c-Myc, Sall4, and NFkB
[209-211]. Genome wide analysis of these transcription factors has identified
approximately 8 000 target genes of c-Myc, 3 200 of Sall4, and 15 000 of NFkB.
These data suggest that many transcription factors bind to a multitude of targets.
We extended our results by characterizing c-Myb binding during estrogen
stimulation. Coincidentally, ER alpha binds to over 10 000 genes [202]
suggesting that ER alpha target genes are as wide spread as c-Myb. In
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conclusion, our data demonstrate that c-Myb target genes are diverse and that cMyb can bind to a large fraction of the genome in a similar fashion as other well
characterized transcription factors.
Materials and Methods
Cells and Culture Conditions

MCF-7 cells (ATCC Manassas, VA) were cultured at 37°/5% CO2 in
DMEM medium (Invitrogen, Carlsbad, CA) supplemented with 10% (v/v) fetal
bovine serum (Invitrogen, Carlsbad, CA). During estrogen starvation, cells
(5X10^5 per/ml) were cultured in phenol red free DMEM (Invitrogen, Carlsbad,
CA) supplemented with 5% charcoal stripped serum (Invitrogen, Carlsbad, CA)
for 48 hr; following starvation 10nM ß-estradiol (Sigma, St. Louis MO) was added
to the medium for 24 hr.
Expression analysis, transcription assays, and immunoprecipitation

Expression analysis, quantitative real time PCR (QPCR), transcriptional
assays, immunoprecipitation, and Western blots were performed as described
[21, 52, 118]. The CXCR4 reporter gene was generated by cloning the 1 kb
region upstream of the CXCR4 gene into the pGL2 basic vector (Invitrogen,
Carlsbad, CA).
Chromatin Immunoprecipitation Assays

Chromatin immunoprecipitation was performed as previously described
[196], but shearing was performed in a 200 µl volume of 50 mM Tris pH 8.0
(Sigma, St. Louis, MO) by adding 40 units of Micrococcal nuclease (USB,
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Cleveland, Ohio) for 10 min at 37°C. EDTA (10 mM) was used to stop the
reaction and nuclei were lysed in 1% v/v SDS. ChIP was performed with anti-Myb
1493 immune serum (10 ul) or anti-Myb monoclonal 1-1 antibodies (Millipore,
Billerica MA) or control non-immune serum (10 ul) or anti-FLAG (Sigma, St. Louis
MO) for 24 hr. Anti-Myb 1493 is a rabbit polyclonal developed against a peptide
HQGTILDNVKNLLEFAE. Primers used for QPCR reactions using SYBR green
(Biorad, Hercules CA) are listed in Supplemental Table 1. ChIP assay results
were normalized for control genes (GAPDH) and control non-immune antibodies.
For ChIP on chip assays, DNA (10ng) was amplified according to manufacturer’s
protocol (www.affymetrix.com). Amplified DNA (6ug) was hybridized to Affymetrix
promoter tiling array 1.0R and data analysis was performed with Model-based
Analysis for Tiling arrays software [212]. Statistical analysis was performed with
PASW 17 (SPSS Inc., Chicago Ill) statistical analysis software. Data were
visualized in Integrated Genome Browser (www.affymetrix.com).
Myb Knockdown

Knockdown of c-myb was performed as previously described, using an
shRNA expression vector kindly provided by Dr. Tom Gonda [54]. Briefly, cells
were transduced with a retrovirus expressing shRNA specific to c-myb or a
scrambled control. Expression of each shRNA was induced for 24 hr with
doxycycline and expression of target genes was analyzed by QPCR as described
above.
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Myb Lentiviral production

N-terminal FLAG-tagged human c-Myb [21] was cloned into the unique
PacI site of the pHR IRES GFP lentiviral vector (kindly provided with packaging
vectors by Dr. Bruce Bunnell, Tulane University) downstream of an EF1 alpha
promoter. Plasmids were transfected into 293 FT cells (Invitrogen, Carlsbad CA)
by calcium phosphate transfection along with the lentiviral packaging plasmid
delta 8.9 and the pMD.G plasmid expressing the vesicular stomatitis virus
glycoprotein. Supernatant was collected at 24 hr intervals for 48 hr. Ultrafiltration
using an Ambion Ultracell 100 kDa NMWL filter unit (Millipore, Billerica MA) was
used to concentrate viral supernatants. Cells were transduced in the presence of
8 ug/ml of polybrene (Sigma, St. Louis MO) and sorted to enrich for GFP+
transduced cells.
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Figure Legends:
Figure 1. The CXCR4 promoter is regulated by Myb proteins

(A) Structure of c-Myb and v-Myb proteins. The diagrams depict the
structure of the c-Myb and v-Myb proteins, which share conserved domains
(shaded) involved in DNA binding and regulation. The oncogenic v-Myb protein is
truncated at both ends and has a number of point mutations represented by
white dots. The locations of the epitopes for antibodies (Abs) 1493 and 1-1 are
indicated. (B) Structure of the CXCR4 gene promoter. The region upstream of
the human CXCR4 gene is diagrammed, with putative Myb binding sites
indicated by gray boxes. The arrow indicates the start site and direction of
transcription. (C) Activation of a CXCR4 reporter gene. A reporter construct
containing the CXCR4 promoter upstream of the luciferase reporter gene was cotransfected into HEK293 cells along with control plasmid (vector) or plasmids
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expressing c-Myb or v-Myb, as indicated. The figure shows reporter gene activity.
Error bars show standard deviation of triplicate assays.
Figure 2. CXCR4 is a c-Myb target gene in MCF-7 cells

(A) MCF-7 cells were deprived of estrogen for 48 hr, then 10nM 17-betaestradiol was added back for 6, 12 or 24 hr, as indicated. Alternatively, cells were
allowed to reach high density (Confl.). The levels of c-myb or CXCR4 were
measured by QPCR. Error bars show standard deviation in triplicate PCR
reactions, and results are relative to the estrogen-deprived cells. (B) Western blot
with anti-c-Myb and anti-beta-actin antibodies of cells grown to high density
(Confl.) or deprived of estrogen for 48 hr followed by adding 10nM 17-betaestradiol for 0, 6, 12 or 24 hr, as indicated. (C) Experimental diagram showing
how cells are deprived of estrogen for 48 hr, stimulated for 24 hr or allowed to
reach high density (Confluent). (D) ChIP was performed on MCF-7 cells
deprived of estrogen for 48 hr, stimulated with 10nM 17-beta-estradiol for 24 hr
or allowed to grow to high density (Confl.). Chromatin complexes were
immunoprecipitated with anti-c-Myb antibodies 1-1 (gray) or 1493 (black).
Enrichment for the CXCR4 promoter was measured by QPCR. Error Bars
represent standard deviation of triplicate PCR reactions.
Figure 3. Flag-c-Myb binds the CXCR4 promoter

(A) Lysate from lentiviral transduced MCF-7 cells was immunoprecipitated
with anti-Flag agarose (Sigma) or control IgG agarose (Santa Cruz). Expression
of FLAG-tagged c-Myb was visualized with anti-c-Myb antibody 1-1 (Millipore) by
Western blot. (B) ChIP assay using anti-FLAG antibodies and chromatin from
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FLAG-c-Myb expressing MCF-7 cells cultured to confluence. QPCR was
performed with primers specific to the CXCR4 promoter and primers designed to
recognize non-specific binding sites within the CXCR4 (NS1), MAT2A (NS2), and
GAPDH promoters. Error bars represent standard deviation from triplicate QPCR
reactions. (C) FLAG-c-Myb MCF-7 cells were deprived of estrogen for 48 hr,
stimulated (Stim.) for 24 hr or grown to high density (Confl.) and subjected to
ChIP assay with anti-FLAG or control IgG. QPCR was performed with primers
specific to CXCR4 promoter and GAPDH. Data are normalized to the IgG control
and GAPDH. Error bars represent standard deviation from triplicate PCR
reactions.
Figure 4. Additional c-Myb target genes

(A) MCF-7 cells were deprived of estrogen for 48 hr then stimulated with
10nM 17-beta -estradiol for 6, 12 or 24 hr, or grown to high density (Confl.).
QPCR was used to measure the levels of CCNB1, EPB41, JUN, and KLF4
RNAs. Error bars show standard deviation in triplicate PCR reactions, and results
are relative to the estrogen-deprived cells. (B) MCF-7 cells were transduced with
retroviral vectors expressing doxycycline inducible shRNAs (scrambled or c-myb
specific). Each cell line was induced for 24 hr with doxycycline and the relative
expression of c-myb, CCNB1, CXCR4, and JUN RNAs was measured by QPCR.
Data are normalized to the non-induced controls.
Figure 5. A switch in c-Myb activity on additional target genes

MCF-7 cells (A,B) or MCF-7 cells expressing FLAG-c-Myb (C) were
deprived of estrogen for two days (open bars), stimulated for 24 hr (gray bars) or
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grown to high density (black bars), then they were crosslinked and chromatin
was isolated and used for ChIP assays using (A) 1-1 (B) 1493 or (C) FLAG
antibodies, as described in Figures 2 and 3. QPCR was performed with primers
specific for the JUN, EPB41, CCNB1 and KLF4 promoters. Data are relative to
control IgG and GAPDH. Error bars represent standard deviation of triplicate
QPCR reactions.
Figure 6. Changing growth conditions trigger massive epigenetic changes

MCF-7 cells were estrogen-deprived for 48 hr then stimulated for 24 hr, or
allowed to grow to high density (Confluent) and samples were used in ChIP on
chip assays to measure genome-wide changes in the H3K4me2 epigenetic mark,
using Affymetrix promoter tiling arrays. (A) Comparison of H3K4me2 marks in
Stimulated (red) and Confluent (blue) cells for representative genes CCNB1,
CCNE1, SND1 and GREB1. Histograms show relative signals and the colored
bars identify statistically significant (p<1x105) regions. Gene diagrams are shown
above chromosome number lines, with units in nucleotides from the March 2006
(NCBI 36/hg18) build of the human genome sequence. (B) Venn diagram
comparing the number of statistically significant (p<1x105) H3K4me2 sites
detected in the two growth conditions. (C) Statistically significant regions (.bed
files) were compared to find overlaps, and the fraction of genome sites identified
by both H3K4me2 and 1-1 (gray) or H3K4me2 and 1493 (black) antibodies in the
two growth conditions is shown.
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Figure 7. Model for a switch in c-Myb activity

A model for changes in c-Myb activity at the CXCR4 promoter is shown.
(A) c-Myb is bound to the promoter and both antibodies, 1493 and 1-1 are able to
bind in ChIP assays. (B) Antibody 1493 is unable to bind c-Myb at the CXCR4
promoter in estrogen-stimulated cells and (C) 1-1 antibody is unable to bind in
confluent cells. The epitopes may be masked by other proteins as shown here, or
affected by conformational changes or post-translational modifications.
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Supplementary Table 1: ChIP primer pairs

Primer Forward

Reverse

NS-1

ACCCACCAAACGGGACTCCATACTC

TCTCTTGACGGCGTGGAATGG

NS-2

TGACATGGACTGCCTTGCATA

ACTGAGAAGCATGACGGACAAGTA

CXCR4

CTGCACCTGACCCTAGTGATGCT

CCAGACCTGGGAATGCTACAGTAGA

GAPDH

GTGCAGGAGTTCATGACCAAC

CACCTGGGCTAGAGTACA

KLF4

CGTGGGGGCTAAAGCTTGT

CAGAGGTGACTATTCAACCGCATA

EPB41

CAGCGAGCAGAGGGTTAAATCTAT

ATGGCCTGCTGGTCAATCT

JUN

GGGGTCGTCTGGCTGCTCGTAGAA

CCAATTGCGCCCACTATAAA

CCNB1

TGGTAACAAAGTCAGTGAAC

TATCAATGACTTTTCCAGTAG

Supplementary Table 2: Expression Primers
Primer

Forward

Reverse

KLF4

ACGATCGTCTTCCCCTCTTT

ACCCTGGGTCTTGAGGAAGT

EPB41

TGGCCCAAAGTGCTGAAGAT

AGTCCGGCCACTGTATCGAA

JUN

CCAATTCGCCCCACTATAAA

CTGGGAAACTCCTGAATTTGTAACT

Supplementary Table 3: Taqman Expression Probes

Primer

Catalog Number

CXCR4

HS00607978_s1

c-myb

Hs00193527_m1

CCNB1

Hs00259126_m1

PPIA

4333763T
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Supporting Data
Introduction
Our data has demonstrated that c-Myb activity and specificity are altered
during epithelial cell proliferation. We identified different sub-populations of cMyb, some of which are more prevalent in highly confluent cell cultures and
others are more prominent in estrogen stimulated lower density cultures. Our
data is supported by evidence from multiple different target genes, which we
initially discovered by ChIP on chip (ChIP on a promoter tiling array). We
performed ChIP on chip with cells grown in different culture conditions because
characterization of the CXCR4 promoter suggested that our antibodies
recognized different sub-populations of c-Myb in a proliferation dependent
manner. Genome wide analysis of c-Myb target genes supported our
observations at the CXCR4 promoter. We performed a lengthy analysis with our
ChIP on chip data, which provided a means to characterize c-Myb activity during
estrogen- stimulated proliferation.
Genomics Suggests that c-Myb Sub-populations exist

As stated above, ChIP on chip analysis identified over 10 000 statistically
significant c-Myb binding sites, which was consistent with previous work with
other transcription factors. However, we extended our genome wide analysis to
identify target genes in two different growth conditions. Our work at the CXCR4
promoter in different growth conditions suggested that different sub-populations
of c-Myb existed (See above Figures). We hypothesized that the 1493 antibodies
and the Ab 1-1 antibodies recognized different fractions of the c-Myb protein in
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different populations of cells. We used a filter script written in R (Dr. Scott Ness)
to analyze overlapping statistically significant binding sites of our ChIP on chip
from both antibodies in each growth condition to determine if these antibodies
were specific for different sub-populations of c-Myb on a genome wide scale.
Supporting Results
1493 Specific Sub-population during different growth conditions

Our QPCR data overwhelming suggests that cells cultured to confluence
express c-Myb and that our 1493 antibodies detect c-Myb at a number of
different genes during cellular confluence even though Ab 1-1 does not detect cMyb at the same promoters. This striking difference prompted us to perform ChIP
on chip in confluent cells and compare the binding sites of 1493 and Ab 1-1
antibodies. Our analysis demonstrated that the 1493 antibody detected over
8,000 target genes in confluent cultures, but only 439 of those binding sites were
bound by Ab 1-1 antibodies (Supporting Figure 1A). QPCR at multiple different
target genes demonstrated that 1493 consistently enriched for target genes
during cellular confluence, but Ab 1-1 did not. Our ChIP on chip data
demonstrated a similar trend on a genome wide scale (Supporting Figure 1A),
but some genes such as ELK4, were bound by both antibodies according to ChIP
on chip. We performed ChIP-QPCR at the ELK4 promoter and demonstrated that
in confluent cultures both antibodies detected c-Myb at the ELK4 promoter
(Supporting Figure 1B). Our results with the 1493 antibody in stimulated cells
demonstrated that these antibodies do not detect the same c-Myb
subpopulations in confluent and stimulated cells because as shown in Supporting
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Figure 1C, only 382 genes are overlapping in confluent and stimulated cells.
These data are supported by our QPCR data demonstrating that 1493 specific cMyb does not bind to CXCR4, KLF4, CCNB1, JUN, or EPB41 in stimulated cells
(See Figure 5 this chapter).
Ab 1-1 c-Myb is distinct from 1493 c-Myb

Our QPCR at other targets such as CXCR4 (See Figure 2 this chapter)
suggest that Ab 1-1 did not detect c-Myb at these targets in confluent cells, but
did detect c-Myb during estrogen stimulation. We compared the binding of each
antibody in estrogen stimulated cells and these genome wide comparisons
demonstrated that Ab 1-1 c-Myb recognized a different set of target genes than
1493 in stimulated cells (Supporting Figure 2A). Some overlap was detected and
in our QPCR, we demonstrated that c-Myb was bound to JUN under both
conditions, but the binding increased 10-fold in estrogen stimulated cells (See
Figure 5 this chapter). A comparison of the Ab 1-1 c-Myb in confluent and
stimulated cells demonstrated that this population of c-Myb bound to distinct
targets in each condition (Supporting Figure 2B). These differences in c-Myb
sub-populations led to the characterization of multiple genes during estrogen
stimulation as described above.
Identification of new target genes and confirmation of known targets

As mentioned previously, we were able to identify new target genes by
ChIP on chip, but our ChIP on chip results confirmed that c-Myb binds to a
number of previously reported target genes. These genes have a variety of
functions and many of which play important cell cycle regulatory roles. In our
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ChIP on chip screen we identified CCNE1 as a direct target gene, which was
speculated to be a target gene, but not confirmed [53]. Furthermore, we
confirmed that CCNB1 [50], KIT [213], MYC [214], and CXCR4 [21] are all c-Myb
target genes. In addition we identified ELK4, EPB41, JUN, KLF4, NANOG, and
SND1 as c-Myb target genes. As shown in Supporting Figure 3, the binding site
for c-Myb was found in intronic regions, promoter regions, and enhancer regions
(CCNE1 ~ 4KB upstream). Interestingly, c-Myb can bind to its own promoter
suggesting that c-Myb can operate a feedback loop to control its own expression.
These data demonstrate c-Myb binding is versatile and encompasses many
different target genes.
Cell Adhesion Governs changes in c-Myb specificity and activity

We observed two different behaviors from our antibodies depending upon
the cell type we utilized. In Jurkat T-cells that grow in suspension, our antibodies
(1493 and Ab 1-1) gave nearly identical results under all conditions examined
(Chapter 2). In contrast, the antibodies displayed opposing behaviors in MCF-7
cells (Chapter 3), which we hypothesized was due to the abundance of cell
adhesion and cell contact because confluent cells gave a strikingly different
result compared with more asynchronous stimulated cells. To test this hypothesis
we characterized antibody efficacy in sub-confluent cultures (asynchronous) and
confluent cultures treated with EDTA compared with confluent cultures.
Lack of cell contacts disrupts epitope masking

MCF-7 cells were plated at medium density ensuring that cells would not
become excessively confluent or plated at high density so they would grow to
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cellular confluence. After a 16-hour incubation, one set of confluent cells was
treated with 5mM EDTA for 2 hours and a second set was allowed to maintain
cell contacts and cell adhesion. After incubation asynchronous (sub-confluent),
confluent, or confluent cells treated with EDTA were subjected to ChIP with both
c-Myb antibodies. As shown in Supporting Figure 4, 1493 antibodies detected cMyb at the CXCR4 promoter during cell confluence, but not in asynchronous,
cultures, which have less cell adhesion. Ab 1-1 showed completely opposite
results detecting c-Myb during asynchronous growth, but not during cell
confluence (Supporting Figure 4). Treatment with EDTA abolished cell: cell
adhesion and cell adhesion to the culture plate, similar to suspension cell growth.
In EDTA treated cells we detected c-Myb at the CXCR4 promoter with both
antibodies mimicking what was observed in Jurkat cells. Therefore, these data
demonstrate that epitope masking in MCF-7 cells is directly related to the
signaling pathways that are regulated by cell adhesion.
v-Myb binds directly to endogenous c-Myb target genes

We have demonstrated that dynamic repositioning regulates c-Myb
specificity and that activity is associated with epitope masking and potential
changes in protein interactions. Since c-Myb does not transform cells even
though it is associated with various types of cancer [29, 32, 35, 215] so we
wanted to determine if the oncogenic derivative of c-Myb, v-Myb binds to different
genes thus ensuring its oncogenic potential. v-Myb and c-Myb activate distinct
sets of endogenous genes [21], but it is unclear if the differences are due to
changes in specificity or activity. Our data thus far suggests two different
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hypothesizes: first, that changes to the structure of c-Myb lead to changes in
specificity and activity at different genes, or second, that changes in structure do
not affect specificity and v-Myb binds to the same target genes, but has different
activity at different times. We developed MCF-7 cells that express v-Myb or
3MutC, a protein mutated in the DNA binding domain, which activates c-Myb
target genes and not v-Myb target genes and performed ChIP assays to
determine occupancy at target genes we identified by ChIP on chip (Supporting
Figure 3).
Transduced MCF-7 cells, which express FLAG tagged versions of v-Myb
or 3MutC [21] were selected for blasticidin resistance by Dr. Fan Liu and stored
for a substantial period time, so we verified that FLAG tagged versions of v-Myb
and 3MutC were expressed. Each mutant protein was immunoprecipitated with
anti-FLAG and Western blot with anti-c-Myb demonstrated that both proteins
were expressed in transduced cells (Supporting Figure 5A). We cultured the cells
to confluence and compared the binding of FLAG c-Myb (Chapter 3) with the
binding of both mutated proteins at CCNB1, KLF4, JUN, and CXCR4. CCNB1 is
essential for the G2/M transition; KLF4 is a reprogramming transcription factor
important for induced pluripotent stem cells; JUN is a known oncogene; and
CXCR4 is the sole receptor for SDF-1. Therefore regulation of these genes is
critically important for cancer and normal cell function. As shown in Supporting
Figure 5B, v-Myb bound to CCNB1, JUN, and CXCR4 promoters; all of these
genes are activated by c-Myb in MCF-7 in response to estrogen (See Chapter 3).
3MutC occupied the JUN and CXCR4 promoters, but not KLF4 or CCNB1
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(Supporting Figure 5B) suggesting that mutation of the DNA binding domain can
affect binding at some targets, but a combination of mutation and truncation
affects binding in a very unique manner. Furthermore, recent work by Ye Zhou
and Dr. John O’Rourke has demonstrated that v-Myb activates CXCR4 and
KLF4, but not CCNB1. Together these data suggest that v-Myb binds to some of
the same genes that c-Myb does, but can have some unique activities in the
absence of direct binding. Furthermore, v-Myb can bind to some genes such as
CCNB1 and have a different activity than c-Myb.

Supporting Discussion
We have shown that changes in c-Myb activity and specificity are induced
by epithelial cell proliferation. Our ChIP on chip results demonstrated that the
changes we have characterized in a small panel of target genes hold true on a
genome wide scale. These results are highly significant (p-value < 1X10-5) and
have been validated by QPCR. QPCR is very sensitive and yields better results
than ChIP on chip. ChIP on chip is also subject to multiple variables that QPCR
is not. For example normalization to input control or to control IgG can yield some
varying data. In addition, we performed whole genome amplification with random
priming. The linearity of this method is controlled for, but it is possible that
specific regions of the genome are amplified better than other regions (GC rich or
AT rich). Therefore, we performed detailed authentication and validation by
identifying Myb response elements in each of the genes we chose to study from
our ChIP on chip results. Taken together, the ChIP on chip results provide a
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foundation for future characterization of c-Myb activity and specificity by QPCR
and other traditional techniques.
Our ChIP on chip results and QPCR data demonstrate that in MCF-7 cells
cell adhesion and cell:cell contacts affect c-Myb activity and specificity. This
phenomenon is cell type specific and is directly related to the cell adhesion
because suspension cells such as Jurkat cells do not display changes in
specificity. In addition treatment of cells with EDTA, which abolishes cell contacts
alters c-Myb binding. Coincidentally, other groups have demonstrated that the
WNT pathway, in particular the TCF family of transcription factors coordinate with
c-Myb at specific target genes in colon epithelial cells (Communicated by Rob
Ramsay) and in our hands TCF3/4 binds to similar Myb targets during both
stimulation and confluence. This suggests that the WNT pathway and c-Myb may
coordinate in MCF-7 cells and the activation or suppression (affected by cell
adhesion) could affect c-Myb activity. It is important to study this coordination
further and determine the role WNT has in c-Myb regulation.
We proposed two different mechanisms of v-Myb regulation. To
investigate these proposals, we performed ChIP with FLAG versions of different
Myb proteins. We discovered that although c-Myb and v-Myb activate entirely
different sets of endogenous genes [21], v-Myb maintains some level of c-Myb
specificity. That is, both proteins can bind to overlapping genes, which is
consistent with reporter gene assays that suggest v-Myb and c-Myb bind to the
same promoters [55, 199]. However, some genes such as KLF4 are not bound
by v-Myb, but are induced upon v-Myb over expression demonstrating that v-Myb
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can have unique indirect activities. On the other hand, in some cases such as
with CCNB1, binding by v-Myb does not translate to activation suggesting that
other forms of regulation are absent or v-Myb functions as a repressor. c-Myb
and v-Myb have been demonstrated to inhibit specific forms of transformation
[216] so it is not unlikely that specific genes can be repressed by v-Myb or c-Myb.
Our results support both suggested hypotheses. First both c-Myb and v-Myb can
bind to the same genes and v-Myb has a different activity; and second, v-Myb
and c-Myb bind to different genes and have unique direct and indirect activities.
Our data suggests that these two mechanisms can be differentiated in a gene
specific manner.
Furthermore, our studies have identified one gene, KLF4, that is bound by
c-Myb and not v-Myb. However, v-Myb can efficiently activate this gene. These
data suggest that unique pathways regulate c-Myb and v-Myb and although
some aspects of these pathways may converge, each protein has a unique
function. KLF4 is important for reprogramming of differentiated cells into
transformed pluripotent stem cells, suggesting that c-Myb may indirectly regulate
oncogenesis through KLF4. Future work dissecting the mechanisms that Myb
proteins utilize to regulate KLF4 is essential to characterize c-Myb induced
oncogenesis.
Supporting Data Materials and Methods
ChIP on chip, Immunoprecipitation, and Western Blot

ChIP was performed as described in Chapter 3 Materials and Methods
and whole genome amplification was performed according to the manufacturer’s
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protocol (Affymetrix). A detailed protocol can be found in Appendix II.
Immunoprecipitation was performed as described in Chapter 2 and Chapter 3.
For sub-confluent cultures cells were seeded 5X10^5 per 15 cm dish and
cultured for 16 hours. During EDTA treatment, cells were seeded at 1X10^6
per/ml and cultured for 16 hours. Then 5 mM EDTA was added for 2 hours under
normal growth conditions.
Lentiviral transduction

Flag tagged versions of v-Myb and 3MutC were cloned into lentiviral
vectors with blasticidin resistant marker. Viral particles were produced as
described in Chapter 2 and Chapter 3 except no flow cytometry was performed.
Cells were selected in 5µg/ml blasticidin and maintained in media with blasticidin.
Western blot was performed as described in Chapter 2 and Chapter 3.
Supporting Figure Legends
Supporting Figure 1: ChIP on chip identifies 1493 Specific Sub-population

(A) Comparison of 1493 binding sites in confluent cells. ChIP on chip was
performed on confluent MCF-7 cells. A comparison of the binding sites between
1493 immune serum and Ab-1-1 monoclonal antibodies was performed with a
script written in R. The Venn diagram demonstrates overlapping genes. (B) ChIP
assay in confluent MCF-7 cells. ChIP was performed with anti-c-Myb 1493
(black) or Ab 1-1 (grey). QPCR at the ELK4 promoter demonstrates that both
antibodies enrich for this gene in confluent cells. (C) ChIP on chip with 1493.
ChIP on chip with confluent MCF-7 cells or estrogen stimulated MCF-7 cells.
Venn diagram represents the overlapping statistically significant binding sites.
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Supporting Figure 2. Ab 1-1 binds to distinct target genes.

(A) Comparison of Ab 1-1 binding sites. ChIP on chip was performed on
stimulated MCF-7 cells with 1493 or Ab 1-1 antibodies. Venn diagram
demonstrates each antibody binds to different subsets of genes. (B) Comparison
of Ab 1-1 in different growth conditions. Venn diagram demonstrates Ab 1-1
binding sites are unique in confluent and estrogen stimulated cells.
Supporting Figure 3. ChIP on chip target genes

ChIP on chip was performed with 1-1 and 1493 antibodies using
chromatin from MCF-7 cells that were deprived of estrogen for 48 hr followed by
24 hr of estrogen stimulation or grown to high density. Histograms show the
normalized (relative to input) signal and red bars mark the statistically significant
(p<1x105) binding sites (histograms) at the indicated promoters. Genes
diagrammed above the number line are on the positive strand, with transcription
from left to right, and genes below the number line are in the opposite orientation.
The images come from Integrated Genome Browser (www.affymetrix.com) and
the number lines show nucleotide numbers in the March 2006 build (NCBI
36/hg18) of the human genome.
Supporting Figure 4. Epitope masking is cell adhesion specific.

ChIP was performed with MCF-7 cells cultured in different growth
conditions. Real time PCR was performed with primers specific for the CXCR4
promoter. Error bars represent standard deviation of triplicate PCR reactions.
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Supporting Figure 5. Oncogenic versions of c-Myb bind to ChIP on chip targets

(A) Western blot of lentiviral transduced MCF-7 cells. Cells were subjected
to IP with anti-FLAG antibodies or control IgG and Western blot was performed
with anti-c-Myb. Each cell line expressed exogenous protein. (B) ChIP of
lentiviral transduced MCF-7 cells. ChIP was performed with anti-FLAG antibodies
or control IgG. Real time PCR was performed with primers specific to CCNB1,
KLF4, JUN, or CXCR4. Error bars represent standard deviation of triplicate PCR.
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Final Words and Implications of Epitope Masking
We identified two sub-populations of c-Myb that are defined by the
recognition or lack thereof by two independent antibodies, ab 1-1 or 1493. Our
experiments were designed in such a manner that all of our ChIP assays were
performed under strikingly different culture conditions. Initially, our hypothesis
was designed to determine if c-Myb specificity was estrogen dependent similar to
what has been observed when cells are treated with prolactin [206]. Consistent
with prior observations, the ab 1-1 specificity was estrogen dependent at most
genes analyzed. In addition, c-Myb recognized by ab 1-1 has increased activity,
which caused an increase in expression of a number of different genes.
However, the inclusion of the 1493 antibody demonstrated that the change
observed was not necessarily a change in specificity because 1493 could detect
c-Myb when ab 1-1 could not. These data combined with FLAG tagged c-Myb
data established that epitope masking was a much more probable explanation for
our observations than changes in binding.
Understanding the mechanism of epitope masking is critical for future
understanding of c-Myb activity during mitogenic stimulation. Single antibody
analysis would suggest that c-Myb specificity is estrogen dependent, but instead
our data demonstrated that it is not solely a change in specificity because c-Myb
can bind to the same genes in both confluent and stimulated conditions. On the
other hand, the changes we see are due to differences in the activity of two
unique forms of c-Myb. These forms of c-Myb are defined by protein interactions
and protein complexes at the promoter of specific genes, which appear to
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change during different stages of estrogen treatment. These data presented do
not uncover the proteins interacting with c-Myb. Furthermore, these data have
demonstrated that regions outside of the DNA binding domain affect activity,
which has been hypothesized based on work that shows Myb proteins activate
distinct sets of genes and was extensively described in Chapter 1 [21, 80]. It is
likely that the regions characterized (conserved domains) here have pivotal roles
in defining what genes are active and at what time.
Our data connects c-Myb activity to changes in cell adhesion and cell
contacts because cellular confluence and estrogen stimulation represent cell
populations that are highly unique. It is known that cell adhesion and signaling
through the WNT pathway is important for cancer progression. Our system
suggests that cell adhesion is important for c-Myb activity and others have
demonstrated that c-Myb is important for epithelial cell cancers suggesting that
the WNT pathway may overlap with changes in c-Myb activity. Results have
demonstrated that estrogen treatment with β-estradiol alters cellular motility and
cell to cell contacts [217-219]. In addition studies have confirmed that estrogen
stimulation (E2) lowers the expression of E-cadherin, which would increase free
ß-catenin and lead to changes at the molecular level [217, 218, 220, 221]. It
seems likely that during cellular confluence ß-catenin is sequestered leading to a
decrease in WNT signaling, but during estrogen treatment the WNT pathway is
activated. c-Myb may interact with components of the WNT pathway in an
estrogen dependent manner and some of these components could account for
epitope masking. Therefore, the work we have presented in this chapter

125

establishes a foundation for the study of how c-Myb interacts with the WNT
pathway in cancer and normal cells and more specifically, which sub-population,
1493 or Ab 1-1, interacts with these components.
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Chapter 4: Discussion
Together these data demonstrate two important points. First, c-Myb
undergoes dynamic repositioning in a cell cycle dependent manner and this
repositioning is gene specific. Second, protein interactions change while c-Myb is
bound to target genes in response to mitogenic stimuli such as estrogen. We
posed the hypothesis that c-Myb has dual functionalities because different subpopulations of cells regulate c-Myb in a time dependent manner. These data
support the hypothesis that c-Myb sub-populations exist (based on the
recognition by different antibodies) and have different activities, which likely
explains how c-Myb regulates different processes. Furthermore, we have
performed ChIP on chip experiments that identified over 10,000 statistically
significant c-Myb target genes demonstrating that c-Myb binds to approximately
1/3 of the human genome. These dual functions of c-Myb are not solely reliant on
changes in protein complexes because c-Myb is partially regulated by changes in
specificity during the cell cycle. Therefore, there is not one single mechanism
governing c-Myb activity and alternatively, multiple mechanisms work together in
a time dependent fashion to mediate specificity and activity. c-Myb may be part
of an extensive complex of proteins that regulates gene expression in much the
same manner as the drosophila dREAM complex in which B-Myb is an important
participant.
Are post-translational modifications cell cycle dependent?
Our laboratory has suggested that c-Myb function is regulated by a
context specific code or sequential post-translational modifications that work in
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concert to regulate c-Myb activity. These modifications can impact protein
interactions [67, 87, 94, 108, 141, 198, 222], but these changes have not been
associated with cell cycle dependent regulation of c-Myb. Our data confirms that
c-Myb is expressed constitutively and repositions onto different promoters and is
expressed constitutively. These data provide a foundation to characterize the
mechanisms controlling c-Myb specificity. If c-Myb is regulated temporally
through post-translational modifications then certain populations of c-Myb
(phosphorylated versus SUMOylated) would be in greater abundance at different
phases of the cell cycle. Serines 11 and 12 are phosphoryated [107] and c-Myb
is hyper-phosphorylated during mitosis [223], which suggests that these residues
could be phosphorylated in mitosis and not in other phases defining a large
fraction of c-Myb molecules. Alternatively, these residues may be modified
constitutively, but only present on a small fraction of c-Myb molecules with
unique activities. Therefore, it is essential to develop antibodies that specifically
recognize specific modifications in order to study these modifications in cells
fractionated according to DNA content. ChIP analysis with these individual
antibodies would allow us to determine if different sub-populations of posttranslationally modified c-Myb bind to different genes under different growth
conditions. Genome wide ChIP correlated with changes in post-translational
modifications would determine what sub-populations of c-Myb are bound to
clinically relevant genes. A comparison of the expression of these target genes
will offer critical insight into the function of c-Myb at specific target genes during
different stages of the cell cycle.
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Are modifications added in sequence?
A chronological ordering of post-translational modifications associated
with activation or repression has been observed with histone modifications [224,
225] and it is entirely likely that c-Myb is regulated in a such a manner.
Therefore, some in vitro analysis with modified versions of c-Myb could
demonstrate if some modifications recruit or signal for a secondary modification.
For example, c-Myb is acetylated by p300 and CBP at the same lysine residues
in the C-termini [96, 98]. While these residues are the primary sites of acetylation
our laboratory has demonstrated that other lysines such as lysine K388 can be
acetylated by p300 (Dr. Fan Liu, unpublished data). It is possible that in the event
of truncation, such as that observed with v-Myb or splice variant 10A where the
C-terminal lysines are deleted, K388 is hyper-acetylated affecting c-Myb activity.
Therefore, if we abolish particular modifications through mutation and analyze for
the presence of other types of modification such as SUMOylation, we may be
able to tease out what modifications occur first and which are associated with an
oncogenic phenotype.
A second approach that can be utilized to characterize post-translational
modifications is to study the protein interactions that result in modifications. cMyb interacts with p300, CBP, CDK6, pim1 kinase, and isomerases. Each of
these proteins has the ability to change c-Myb activity through post-translational
modifications. Acetylation increases c-Myb affinity for CBP, which suggests that
some interactions occur in sequential manner. It is possible that p300 acetylates
c-Myb before other modifiers such as E3 ubiquitin ligases can cause
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SUMOylation or ubiquitinylation. Characterizing the time dependent nature of
different protein interactions could offer insight about what modifications change
c-Myb activity.
c-Myb is displaced from promoters during estrogen deprivation
We demonstrated that in Jurkat T-cells c-Myb repositioned and changed
specificity during the cell cycle, but in MCF-7 breast cells, c-Myb did not
reposition and epitopes were masked suggesting that protein interactions
changed at the promoter. Therefore, repositioning is not the only mechanism cMyb uses to control gene expression. Our data in MCF-7 cells overwhelmingly
suggests that epitope masking occurs. However in estrogen deprived cells c-Myb
did not significantly bind to the target genes we identified. c-Myb was expressed
in deprived cells so the lack of binding is not simply due to changes in c-Myb
expression. The lack of binding to targets during estrogen stimulation in spite of
stable expression suggests that in estrogen deprived cells c-Myb underwent
repositioning or was simply displaced from promoters. These data coincide with
our data in Jurkat cells where c-Myb was expressed and bound to DNA, but
oscillated from one promoter to the other. It is likely that in deprived cells c-Myb
is shuttled to a different set of promoters, which are yet to be identified.
c-Myb partners change when c-Myb does not
Epitope masking implies that c-Myb is part of a protein complex, which
affects c-Myb activity. Potential masking occurred at two very highly conserved
regions in the c-Myb protein suggesting that these regions are important for
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protein interactions. During cell confluence and estrogen deprivation, c-Myb
activity was regulated by the availability of epitopes and not by the oscillation of
c-Myb from one promoter to another. This suggests that a second mechanism
regulates c-Myb activity, a mechanism that exploits c-Myb protein interactions to
change activity. It is likely that c-Myb can bind to the same genes during both
cellular confluence and estrogen stimulation, however the factors that cooperate
with c-Myb during each growth condition presumably change and alter activity.
Therefore, it is important to identify what proteins interact with c-Myb in each
condition. For example, other transcription factors such as beta catenin, a WNT
signaling protein affected by cell confluence and cell junctions, could interact with
c-Myb in stimulated cells, but not confluent cells. Experiments that would define
these mechanisms include those detailed below.
In order to identify proteins that interact with each domain (1493 or Ab 1-1)
a yeast two-hybrid genetic screen could be performed with isolated fragments of
each domain. This type of screening would identify potential interacting partners
and in many cases these partners maybe expressed in a tissue specific manner.
Alternatively, cells that express-tagged versions of c-Myb could be used to
perform proteomics in multiple conditions such as estrogen stimulated cells or
those cultured to confluence. These experiments would identify which
interactions are the most critical for c-Myb activity at different stages of
proliferation or differentiation. There are many molecules of c-Myb within one cell
and it is clear that the protein exists in sub-stoichiometric fractions with different
activities. It has not been demonstrated that c-Myb is sequestered during
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different stages of proliferation, but c-Myb colocalizes with FLASH in distinct
nuclear foci [116], which suggests that some protein interactions can sequester
c-Myb into different compartments. Therefore, the identification of c-Myb
interacting partners could determine if c-Myb has different localization patterns
when it is inactive. Estrogen deprived provide good model to study changes in
both DNA binding and protein interactions. Since c-Myb in estrogen-deprived
cells does not bind to a number of different targets, it suggests that in these cells
c-Myb might be sequestered. As a whole, these experiments will characterized cMyb protein interactions in different growth conditions and determine what
mechanisms regulate c-Myb activity.
Do oncogenic versions reposition differently?
It is clear that truncated and mutated versions of c-Myb, like v-Myb, are
oncogenic. How these versions transform cells is unknown, but it is known that
these proteins regulate distinct sets of endogenous genes [21]. These proteins
can bind to the same target genes in reporter gene assays [55], suggesting that
the oncogenic version maintains some level of specificity. Our new data suggests
that oncogenic versions bind to some of the same genes as wild-type versions of
c-Myb. However, this binding might be deregulated in different stages of
proliferation or differentiation. To extend our data, cells expressing different
variants of c-Myb can be separated into different stages of the cell cycle to
characterize if these versions bind to target genes when c-Myb does not. We
discovered that c-Myb bound to the CCNB1 promoter in a cell cycle dependent
manner. v-Myb can bind to CCNB1promoter in MCF-7 cells so it is plausible that
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v-Myb regulation of CCNB1 is deregulated during the cell cycle. Alternatively, it is
likely that binding by v-Myb does not always translate into activation. However, at
some genes such as CXCR4, v-Myb transactivates the gene to a greater extent
than c-Myb [21] suggesting that just the ability to bind could increase activity.
Therefore to differentiate between these two scenarios we must identify whether
v-Myb repositioning occurs in a manner similar to c-Myb and if v-Myb interacting
partners change in response to external stimuli.
Application of fractionation to characterize stem cells
c-Myb is not only necessary for proper proliferation, it is essential for
hematopoiesis [38]. In addition, it is expressed in proliferating HSCs [23] and
regulates genes such as CD34 [60] that are expressed on primitive HSCs.
Furthermore, loss of c-Myb results in defects in self renewal due to impaired
proliferation [226] suggesting that the activity of c-Myb during differentiation is
critical. Moreover, different subsets of adult stem cells have been with Hoescht
dye by changes in side population sorting. These sub-populations are
predisposed to differentiate into specific lineages [227]. This suggests that the
activity of some transcription factors, such as c-Myb, could be responsible for the
differences in “stemness.”
We have expanded a technique to analyze the occupancy of transcription
factors during the cell cycle. We can apply our cell cycle analysis with stem cells
presorted according to side population scatter. Live side populations can be
sorted into three different stem cell compartments and the cell cycle of each
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compartment could be characterized with our technique. Therefore, c-Myb
activity could be analyzed in different populations of stem cells, where c-Myb is
highly expressed and regulates proliferation. To extend these results, the level of
c-Myb could be manipulated in mouse models to determine how decreases in cMyb expression affect the cell cycle of primitive stem cells. These experiments
are not limited to using Hoechst dye to identify side populations. Populations of
cells could be defined by the expression of different cell surface markers and
characterized by cell cycle fractionation. These experiments would characterize
the activity and specificity of c-Myb during different stages of hematopoiesis.
These experiments would enhance our knowledge of c-Myb activity in cell
subsets during differentiation and if applied to some types of cancer cells, could
be used to characterize changes in c-Myb activity in cancer.
Implications for the future
It is clear that c-Myb regulation of gene expression is multifaceted and the
mechanisms regulating c-Myb activity are complex. If we continue to explore the
hypothesis that protein interactions and post-translational modifications dictate cMyb activity, it is possible to make tremendous strides in the Myb field. We now
have the ability to study small fractions of cells. Fractionation of different subpopulations of cells may identify highly active forms of one protein. Future
experiments will determine whether protein complexes, modifications, or both,
define specific sub-populations of c-Myb and will enhance our understanding of
how c-Myb becomes oncogenic.
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Appendices
Appendix I: Specificity in primary cells
Characterization of c-Myb in primary cells
Identification of c-Myb target genes is essential for the characterization of
c-Myb activity. c-Myb target genes have a variety of functions including functions
in proliferation, differentiation, and apoptosis. However, the identification of target
genes has been limited to pre-established cell lines. For example, c-Myb binds to
the CCNB1 promoter, but the binding has been shown only in Jurkat cells, COS7
cells, and K562 cells [50]. These cells are all established cell lines that have
documented expression of c-Myb. Jurkat cells dramatically over-express c-Myb.
It is likely that c-Myb activity is deregulated in these cells. In addition, many
pathways such as the p53 pathway are amplified or suppressed in some cell
lines, suggesting that some target genes may be the product of multiple factors.
For example, p53 and c-Myb interact with each other in certain cell types. Cell
lines with deleted p53 may exhibit changes in c-Myb activity. Since it is difficult to
determine the true activity of c-Myb with cell lines, we used mobilized CD34+ in
order to characterize c-Myb activity in primary cells. c-Myb is expressed in
CD34+ immature hematopoietic cells and these cells can be induced to
differentiate or proliferate, which allows for the characterization of c-Myb activity
at different stages of hematopoiesis.
As discussed, c-Myb plays a complex role during proliferation and
differentiation. Given the puzzling fact that c-Myb binds to and activates genes
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such as MPO, a myeloid specific differentiation marker expressed in terminally
differentiated cells, we wanted to characterize c-Myb specificity and activity
during different stages of differentiation. To this end we used cytokine treatment
to both expand and differentiate cells into myeloid and erythroid specific
progenitors. CD34+ cells were expanded for 4 days in media that contained IL-3,
IL-6, SCF, and Flt-3 ligand. Cells were then shifted into medium, which contained
either IL-6 with GM-CSF or IL-3, SCF with EPO for 10 days. We proceeded to
differentiate these two lineages further with a treatment of EPO or G-CSF for 5
more days. We confirmed that c-myb RNA was relatively constant during
erythroid development and decreased approximately 3 fold or 9 fold in D10 or
D15 myeloid cells, respectively [118]. We performed ChIP analysis at different
time points to determine c-Myb specificity at both proliferative targets such as
CCNB1 or differentiation markers such as MPO and EPB41, a myeloid specific or
erythroid specific marker, respectively. These data demonstrate that c-Myb
specificity is cell type specific and different populations of cells have varied subpopulations of c-Myb with different binding activity.
Results
c-Myb specificity in Day 4 proliferating progenitors

Stimulated CD34 cells exhibit a typical cell cycle distribution according to
Hoechst 33342 DNA content dye. Prior to stimulation, 95% of cells are in G0/G1,
however upon cytokine stimulation cells enter the cell cycle and expand
approximately 4-fold over 4 days (Figure 1A). These actively proliferating cells
have increased c-myb expression relative to non-proliferating cells [118], but
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ChIP analysis demonstrated that c-Myb was not bound to the proliferative
markers, CCNB1 or CCNE1 (Figure 1B). However, c-Myb was bound to c-Kit and
EPB41, a gene normally associated with red blood cell membrane structure.
Some reports suggest that variants of EPB41 are essential for proper
proliferation [228]. Despite expression of CXCR4 in these cells, c-Myb did not
occupy the promoter. Consistent with the function of MPO, c-Myb did not occupy
the MPO promoter in this population. These results demonstrate that c-Myb
specificity is tightly regulated in stimulated CD34+ cells and that c-Myb does not
bind to differentiation specific markers when they are not highly expressed.
c-Myb specificity is lineage specific in committed progenitors

As described we differentiated our proliferating day four progenitors and
harvested them at day 10. During myeloid specific differentiation, the level of cMyb decreases approximately 3-fold so we expected the level of c-Myb
specificity and activity to decrease, but strikingly, we observed the opposite
trend. c-Myb remained bound to the c-Kit promoter, but at least one of two
antibodies (1493 or Ab 1-1 refer to chapter 3) detected c-Myb at the CCNB1 or
CCNE1 promoter in these myeloid progenitors (Figure 2). c-Myb was detected at
the MPO promoter consistent with the hypothesis that c-Myb binds to this
promoter in myeloid progenitor cells populations. In contrast, c-Myb did not
occupy the MPO promoter in erythroid progenitors, but did occupy CXCR4, c-Kit,
CCNB1, and CCNE1 as detected by at least one c-Myb antibody (1493 or Ab 11), We presume that the antibodies differ in detection due to the documented
epitope masking we have demonstrated in Chapter 3. Taken together these data
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demonstrate that c-Myb specificity is lineage specific and that low levels of c-myb
mRNA do not correspond to the level of c-Myb binding in primary differentiated
cells.
More committed progenitors display less c-Myb activity

c-myb expression decreased as cells differentiated, but our QPCR data
demonstrated that c-myb transcript was still detectable after 15 days of
differentiation with Epo or G-CSF [118] so we performed ChIP after 15 days of
differentiation. Our results with both myeloid and erythroid lineages was more
consistent with the level of RNA transcript. We did not detect c-Myb at the MPO,
EPB41, CCNB1, or c-Kit promoters in either cell type, but we did detect c-Myb at
the CCNE1 gene in myeloid cells with two anti-c-Myb antibodies, but not in
erythroid lineage cells (Figure 3). These data demonstrate that more committed
progenitors have decreased c-myb RNA transcript levels relative to day 4 or day
10 progenitors and have c-Myb protein that binds to a different subset of genes
or a smaller subset of genes since we only detected c-Myb at CCNE1 in these
cells.
c-Myb activity is altered in the most immature progenitors.

We have demonstrated that c-Myb protein in progenitor cell populations
has different specificity. However, CD34+ cells represent a crude mixture of
different cell types. CD34+ is not an accurate measure of stem cell capabilities
because other cell surface markers are necessary to accurately define stem cell
populations. As a means of purifying immature stem cells from a heterogenous
CD34 population we isolated cells based on the expression aldehyde
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dehydrogenase expression. Aldehyde dehydrogenase is expressed in more
immature stem cells that express the cell surface markers CD34, CD133, and Kit.
This population is more accurately defined and therefore represents a more
homogenous population of cells. Cells were stained with an aldefluor selection kit
(Stem Cell Technology, Vancouver, Canada) and fractionated by fluorescence
activated cells sorting. Aldefluor positive cells express aldehyde dehydrogenase
and only live cells with intact membranes can retain the fluorescent signal so this
technique enriched for only live stem cell populations. We performed ChIP
assays with aldefluor positive cells and analyzed c-Myb occupancy at the KIT,
CCNE1, CCNB1, and CXCR4 promoters. We detected c-Myb at the KIT
promoter in positive cells, which was consistent with what we observed in day 4
CD34+ cells (Figure 4). However, we observed a completely different result at
the CCNB1, CCNE1, and CXCR4 promoters. We detected a significant
enrichment at both the CCNB1 and CCNE1 promoters in positive cells and a
more modest enrichment at the CXCR4 promoter (Figure 4). These data suggest
that c-Myb binds to CCNB1, CCNE1, KIT, and CXCR4 in primitive progenitor cell
populations, but during stimulated proliferation and differentiation, c-Myb
specificity is dramatically different demonstrating that c-Myb specificity and
activity are tightly regulated during both proliferation and differentiation.
Materials and Methods
Cells and Culture Conditions

Cytokine-mobilized CD34+ cells (Fred Hutchison Cancer Research Center
Large-Scale Cell Processing Core) were cultured in IMDM media (Invitrogen,
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Carlsbad, CA) supplemented with BITS serum substitute, IL-3 (20 ng/ml), IL-6
(20 ng/ml), Stem Cell Factor (100 ng/ml), and FLT-3 ligand (100 ng/ml) (all from
Stem Cell Technology, Vancouver, Canada) for four days. Cells were then
differentiated as previously described [118].
Aldefluor selection and ChIP assays

CD34+ cells were harvested directly from the storage vial and stained for
aldehyde dehydrogenase expression according to manufacturer’s protocol (Stem
Cell Technology, Vancouver, Canada). Cells were by FACS and were fixed as
per ChIP assay. A modified micro-ChIP protocol was performed as described
[195] and detailed in Chapter 2 and 3. All primer pairs are listed in Chapter 2 and
3 Supplementary Tables except for those listed in Appendix I Table 1.
Implications
This short analysis of c-Myb specificity in primary human CD34+ cells has
not been previously reported. Extensive work has been performed in mice,
however identification and characterization of c-Myb specificity is unclear,
especially in human stem cells. Here we can demonstrate that genes identified in
cell lines such as CCNB1, CCNE1, and c-Kit are c-Myb target genes in primary
human cells. However, c-Myb occupancy at these targets is restricted cells of a
particular cell type, such as day 10 differentiated relative to day 15 differentiated.
These results suggest that c-Myb specificity is not redundant in every cell type
and the external cues a cell receives (myeloid versus erythroid) impact the target
genes c-Myb activates. This was clearly demonstrated by c-Myb specificity at the
MPO and EPB41 targets. MPO occupancy was restricted to day 10 myeloid
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progenitors. Furthermore, the occupancy of c-Myb at proliferative genes such as
CCNB1 and CCNE1 was found in a variety of cell types, especially the most
immature stem cells. It is clear from these results that future research and newer
technology is necessary to clearly define c-Myb function in hematopoiesis.
Defining the mechanisms that differentiate c-Myb specificity in each cell type is a
critical stepping-stone to characterize c-Myb oncogenesis.
Figure Legends and Tables
Figure 1. c-Myb specificity in stimulated CD34+ cells.

(A) Cell cycle analysis of CD34+ cells. Cells were fixed in ethanol directly
from the storage vial without any stimulation with proliferative cytokines (Left
panel) or after 4 days of stimulation with a cytokine cocktail (Right panel). The
percentage of cells in each phase is shown. (B) ChIP analysis with CD34+ cells.
ChIP was performed with anti-c-Myb 1493 antibodies on CD34+ cells stimulated
in culture for 4 days. Data is normalized to control antibody.
Figure 2. c-Myb specificity is lineage specific.

ChIP with differentiated CD34+ cells. Stimulated CD34+ cells (Day 4)
were harvested and placed in cytokine specific medium to initiate myeloid or
erythroid specific differentiation. Day10 progenitors were subjected to ChIP with
anti-c-Myb 1493 and Ab 1-1 antibodies. Erythroid cells are represented as black
and gold bars and myeloid cells are white and grey bars.
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Figure 3. Successive differentiation changes c-Myb specificity

ChIP with Day 15 differentiated cells. Day10 progenitors were harvested
and induced to further differentiate with either erythropoietin or G-CSF for five
more days. ChIP was performed with anti-c-Myb 1493 or Ab 1-1 antibodies.
Erythroid cells are represented as black and gold bars and myeloid cells are
white and grey bars.
Figure 4. c-Myb binds to genes in immature stem cells.

ChIP with aldefluor positive CD34+ cells. Cells were stained for aldehyde
dehydrogenase expression and sorted by FACS. ChIP was performed with antic-Myb 1493 or Ab 1-1 antibodies. Error bars represent triplicate PCR reactions.

Appendix I Table 1: ChIP primer pairs
Gene
KIT

Forward

Reverse

GCGGTGCCAGGAGCTCCTAA

CTCCCCAGACAATAAAGGTCGACT

MPO

CCCTAACTGCATCACTAACCACAA

GCGCAGGACCAAGATAACTT
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Figure 1
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Figure 2:
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Figure 3:
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Figure 4
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Appendix II: Detailed Whole Genome Amplification Protocol
Whole Genome Amplification (WGA) Protocol
Supplies:

Native Taq polymerase (Invitrogen, 18038-042 5U/ul)
10X Taq Buffer without MgCl (Comes with Taq)
50mM MgCl2 (comes with Taq)
100uM stock of separate dNTPs (Promega Catalog number U1330)
20uM stock of dUTP (Applied Biosystems Catalog number N808-0095)
Primer A (GTTTCCCAGTCACGGTCNNNNNNNNN) HPLC PURIFIED
Primer B (GTTTCCCAGTCACGGTC) Normal purification
S-300 columns from Amersham (27-5130-01)
Always use Native Taq polymerase and its buffer as it is the most efficient and it
must come from Invitrogen.
Step 1:

Quantitate ChIP DNA by Nano drop (For smaller amounts of DNA use a
picogram detection kit. There are some available.) Use 10 nanograms of DNA for
the concentration of primer used below
Reaction Set Up

2 ul of 10X buffer
2ul of 50mM MgCl2
1 ul of 5mM dNTPs, mixed from 25mM stock.
1 ul of 1mg/ml BSA
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2 ul of Native Taq (5U/ul Invitrogen)
1.16 ul of 40uM primer A
Up to 20 ul of water

PCR Conditions.

94 degrees for 2 min
4-5 cycles:
94 for 60 sec.
28 for 1 min
Ramp from 28-55 at 0.1 degrees/sec
55 for 2 min
68 for 30 sec
Final Extension:
68 for 8 min.
Purify DNA

Use two columns for each sample as follows:
Centrifuge 1500 RPM to remove buffer
Add 200ul of 10mM Tris pH 7.4 to wash
Centrifuge 1500 RPM
Dilute sample to 50 ul
Add samples to the column
Centrifuge 1500 RPM
Collect flow through
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Repeat without a second dilution step.

Reaction 2 Setup

10 ul of Sample from Reaction 1
5ul of 10x buffer
1.875ul of dNTPs (10mM of dATP, dGTP, dCTP, and 8mM dTTP with 2mM
dUTP)
1.5ul of MgCl2 50 mM
2-4ul of 100uM Primer B
1ul Native Taq (5U/ul) Invitrogen
Up to 50 ul of water
(Alternatively use Taq MasterMix with a spike of dUTP)

PCR conditions

94 for 2 min
15 cycles of:
94 for 30 seconds
45 for 30 seconds
55 for 30 seconds
72 for 1 min
Then 15 cycles of:
94 for 30 seconds
45 for 30 seconds
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55 for 30 seconds
72 for 1 min but add 5 seconds every cycle
The first cycle will extend for 1 min and subsequent cycles will extend for 1:05,
then 1:10 for each consecutive sample.
Run PCR reaction (5ul) on a 2% agarose gel. A smear should be visible in the
range of the original chip DNA.

Verification

1st.- Take input DNA and perform PCR with 3-5 gene specific primers.
All of the primers should amplify a known product by regular PCR ensuring there
is complete coverage of the genome.

2nd- Take all of the samples and check them by real time PCR with primers that
have displayed significant enrichment. Amplified samples should maintain the
same level of enrichment as demonstrated prior to amplification. If they do not
then further optimization will be necessary to maintain linear amplification. For
example, try reducing the number of cycles. This can be different with different
samples. If the ChIP assays have very little background it is possible to perform a
higher number of cycles. If everything looks correct than sample can be pooled
purified with mini-elute columns (Qiagen, Catalog number 28004), which will give
the most product back with minimal losses.
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